Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
24 "Mortality"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Cardiovascular Risk/Epidemiology
Article image
Impact of New-Onset Diabetes after Transplantation on Cardiovascular Risk and Mortality in Korea: A Nationwide Population-Based Study
Seung Shin Park, Bo Kyung Koo, Sanghyun Park, Kyungdo Han, Min Kyong Moon
Received February 18, 2024  Accepted June 17, 2024  Published online September 12, 2024  
DOI: https://doi.org/10.4093/dmj.2024.0078    [Epub ahead of print]
  • 1,000 View
  • 31 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Limited data are available on the adverse effects of new-onset diabetes after transplantation (NODAT) in solid organ transplantation (TPL) other than kidney. This study aimed to identify the risk of complications associated with NODAT in recipients of kidney, liver, or heart TPL.
Methods
Using the Korean National Health Insurance Service database, recipients of kidney, liver, or heart TPL between 2009 and 2015 were identified. The incidence of coronary artery disease (CAD), cerebrovascular accident (CVA), and malignancy was compared across groups with NODAT, pretransplant diabetes mellitus (DM), and without DM using Cox regression analysis.
Results
A total of 9,632 kidney, liver, or heart TPL recipients were included. During the median follow-up of 5.9 years, NODAT independently increased the incidence of CAD (hazard ratio [HR], 2.46; 95% confidence interval [CI], 1.39 to 4.30) and overall mortality (HR, 1.48; 95% CI, 1.14 to 1.95) compared to the reference group even after adjustment for confounders; this was more prominent in kidney TPL than in liver TPL. The risk of CVA was significantly increased by pretransplant DM but not by NODAT in both kidney and liver TPL (HR, 2.47; 95% CI, 1.68 to 3.65; and HR, 3.18; 95% CI, 1.07 to 9.48, respectively). NODAT increased the risk of malignancy in the crude model, which lost its statistical significance after confounder adjustment.
Conclusion
NODAT independently increases the risk of CAD and mortality after TPL, which is more evident in kidney recipients. There was no additional increased risk of CVA or malignancy with NODAT in solid organ TPL.
Metabolic Risk/Epidemiology
Article image
Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality
Rosa Oh, Seohyun Kim, So Hyun Cho, Jiyoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim
Received January 26, 2024  Accepted June 17, 2024  Published online August 28, 2024  
DOI: https://doi.org/10.4093/dmj.2024.0042    [Epub ahead of print]
  • 1,392 View
  • 99 Download
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Given the association between nonalcoholic fatty liver disease and metabolic risks, a new term, metabolic dysfunction- associated steatotic liver disease (MASLD) has been proposed. We aimed to explore the association between MASLD and all-cause, cause-specific mortalities.
Methods
We included individuals with steatotic liver disease (SLD) from the Korean National Health Insurance Service. Moreover, SLD was defined as a fatty liver index ≥30. Furthermore, MASLD, metabolic alcohol-associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction (MD) were categorized based on alcohol consumption and MD. We also analyzed all-cause, liver-, cancer-, hepatocellular carcinoma (HCC)- and cardiovascular (CV)-related mortalities.
Results
This retrospective nationwide cohort study included 1,298,993 individuals aged 40 to 79 years for a mean follow-up duration of 9.04 years. The prevalence of MASLD, MetALD, and ALD with MD was 33.11%, 3.93%, and 1.00%, respectively. Relative to the “no SLD” group, multivariable analysis identified that MASLD (adjusted hazard ratio [aHR], 1.28; 95% confidence interval [CI], 1.26 to 1.31), MetALD (aHR, 1.38; 95% CI, 1.32 to 1.44), and ALD with MD group (aHR, 1.80; 95% CI, 1.68 to 1.93) have a significantly higher risk of all-cause mortality. Furthermore, MASLD, MetALD, ALD with MD groups showed higher liver-, cancer- and HCC-related mortality than “no SLD” group. While all-cause specific mortalities increase from MASLD to MetALD to ALD with MD, the MetALD group shows a lower risk of CV-related mortality compared to MASLD. However, ALD with MD group still have a higher risk of CV-related mortality compared to MASLD.
Conclusion
SLD is associated with an increased risk of all-cause, liver-, cancer-, HCC-, and CV-related mortalities.

Citations

Citations to this article as recorded by  
  • High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction
    Seong-Uk Baek, Jin-Ha Yoon
    Biomolecules.2024; 14(11): 1468.     CrossRef
Cardiovascular Risk/Epidemiology
Article image
Psychotic Disorders and the Risk of Type 2 Diabetes Mellitus, Atherosclerotic Cardiovascular Diseases, and All-Cause Mortality: A Population-Based Matched Cohort Study
You-Bin Lee, Hyewon Kim, Jungkuk Lee, Dongwoo Kang, Gyuri Kim, Sang-Man Jin, Jae Hyeon Kim, Hong Jin Jeon, Kyu Yeon Hur
Diabetes Metab J. 2024;48(1):122-133.   Published online January 3, 2024
DOI: https://doi.org/10.4093/dmj.2022.0431
  • 2,276 View
  • 198 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The effects of psychotic disorders on cardiometabolic diseases and premature death need to be determined in Asian populations.
Methods
In this population-based matched cohort study, the Korean National Health Insurance Service database (2002 to 2018) was used. The risk of type 2 diabetes mellitus (T2DM), acute myocardial infarction (AMI), ischemic stroke, composite of all cardiometabolic diseases, and all-cause death during follow-up was compared between individuals with psychotic disorders treated with antipsychotics (n=48,162) and 1:1 matched controls without psychiatric disorders among adults without cardiometabolic diseases before or within 3 months after baseline.
Results
In this cohort, 53,683 composite cases of all cardiometabolic diseases (during median 7.38 years), 899 AMI, and 1,216 ischemic stroke cases (during median 14.14 years), 7,686 T2DM cases (during median 13.26 years), and 7,092 deaths (during median 14.23 years) occurred. The risk of all outcomes was higher in subjects with psychotic disorders than matched controls (adjusted hazard ratios [95% confidence intervals]: 1.522 [1.446 to 1.602] for T2DM; 1.455 [1.251 to 1.693] for AMI; 1.568 [1.373 to 1.790] for ischemic stroke; 1.595 [1.565 to 1.626] for composite of all cardiometabolic diseases; and 2.747 [2.599 to 2.904] for all-cause mortality) during follow-up. Similar patterns of associations were maintained in subgroup analyses but more prominent in younger individuals (P for interaction <0.0001) when categorized as those aged 18–39, 40–64, or ≥65 years.
Conclusion
Patients with psychotic disorders treated with antipsychotics were associated with increased risk of premature allcause mortality and cardiometabolic outcomes in an Asian population. This relationship was more pronounced in younger individuals, especially aged 18 to 39 years.
Complications
Article image
Impact of Hyperglycemia on Complication and Mortality after Transarterial Chemoembolization for Hepatocellular Carcinoma
Sun Joon Moon, Chang Ho Ahn, Yun Bin Lee, Young Min Cho
Diabetes Metab J. 2024;48(2):302-311.   Published online January 3, 2024
DOI: https://doi.org/10.4093/dmj.2022.0255
  • 1,823 View
  • 202 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Current guidelines regarding periprocedural glycemic control to prevent complications after nonsurgical invasive procedures are insufficient. Transarterial chemoembolization (TACE) is a widely used treatment for unresectable hepatocellular carcinoma. We aimed to investigate the association between diabetes mellitus (DM) per se and the degree of hyperglycemia with postprocedural complications after TACE.
Methods
A total of 22,159 TACE procedures performed at Seoul National University Hospital from 2005 to 2018 were retrospectively analyzed. The associations between DM, preprocedural glycosylated hemoglobin (HbA1c), and periprocedural average glucose with postprocedural adverse outcomes were evaluated. The primary outcome was occurrence of postprocedural bacteremia. Secondary outcomes were acute kidney injury (AKI), delayed discharge and death within 14 days. Periprocedural glucose was averaged over 3 days: the day of, before, and after the TACE procedures. Propensity score matching was applied for procedures between patients with or without DM.
Results
Periprocedural average glucose was significantly associated with bacteremia (adjusted odds ratio per 50 mg/dL of glucose, 1.233; 95% confidence interval, 1.071 to 1.420; P=0.004), AKI, delayed discharge, and death within 14 days. DM per se was only associated with bacteremia and AKI. Preprocedural HbA1c was associated with delayed discharge. Average glucose levels above 202 and 181 mg/dL were associated with a significantly higher risk of bacteremia and AKI, respectively, than glucose levels of 126 mg/dL or lower.
Conclusion
Periprocedural average glucose, but not HbA1c, was associated with adverse outcomes after TACE, which is a nonsurgical invasive procedure. This suggests the importance of periprocedural glycemic control to reduce postprocedural complications.

Citations

Citations to this article as recorded by  
  • Serum CYFRA 21-1 and CK19-2G2 as Predictive Biomarkers of Response to Transarterial Chemoembolization in Hepatitis C–related Hepatocellular Carcinoma Among Egyptians: A Prospective Study
    Mohamed Y. Taher, Ehab Hassouna, Abeer El Hadidi, Omar El-aassar, Mohamed Fathy Bakosh, Mohamed Said Shater
    Journal of Clinical and Experimental Hepatology.2025; 15(1): 102405.     CrossRef
Metabolic Risk/Epidemiology
Article image
Low Household Income Status and Death from Pneumonia in People with Type 2 Diabetes Mellitus: A Nationwide Study
You-Bin Lee, So Hee Park, Kyu-na Lee, Bongsung Kim, So Yoon Kwon, Jiyun Park, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim
Diabetes Metab J. 2023;47(5):682-692.   Published online June 22, 2023
DOI: https://doi.org/10.4093/dmj.2022.0184
  • 2,543 View
  • 151 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We explored the risk of death from pneumonia according to cumulative duration in low household income state (LHIS) among adults with type 2 diabetes mellitus (T2DM).
Methods
Using Korean National Health Insurance Service data (2002 to 2018), the hazards of mortality from pneumonia were analyzed according to duration in LHIS (being registered to Medical Aid) during the 5 years before baseline (0, 1–4, and 5 years) among adults with T2DM who underwent health examinations between 2009 and 2012 (n=2,503,581). Hazards of outcomes were also compared in six groups categorized by insulin use and duration in LHIS.
Results
During a median 7.18 years, 12,245 deaths from pneumonia occurred. Individuals who had been exposed to LHIS had higher hazards of death from pneumonia in a dose-response manner (hazard ratio [HR], 1.726; 95% confidence interval [CI], 1.568 to 1.899 and HR, 4.686; 95% CI, 3.948 to 5.562 in those exposed for 1–4 and 5 years, respectively) compared to the non-exposed reference. Insulin users exposed for 5 years to LHIS exhibited the highest outcome hazard among six groups categorized by insulin use and duration in LHIS.
Conclusion
Among adults with T2DM, cumulative duration in LHIS may predict increased risks of mortality from pneumonia in a graded dose-response manner. Insulin users with the longest duration in LHIS might be the group most vulnerable to death from pneumonia among adults with T2DM.

Citations

Citations to this article as recorded by  
  • Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes
    Ji Yoon Kim, Sojeong Park, Minae Park, Nam Hoon Kim, Sin Gon Kim
    JAMA Network Open.2024; 7(11): e2443918.     CrossRef
Review
Cardiovascular Risk/Epidemiology
Article image
Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus
Takayoshi Sasako, Toshimasa Yamauchi, Kohjiro Ueki
Diabetes Metab J. 2023;47(2):185-197.   Published online January 12, 2023
DOI: https://doi.org/10.4093/dmj.2022.0325
  • 7,380 View
  • 425 Download
  • 13 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   ePub   
In the management of diabetes mellitus, one of the most important goals is to prevent its micro- and macrovascular complications, and to that end, multifactorial intervention is widely recommended. Intensified multifactorial intervention with pharmacotherapy for associated risk factors, alongside lifestyle modification, was first shown to be efficacious in patients with microalbuminuria (Steno-2 study), then in those with less advanced microvascular complications (the Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care [ADDITION]-Europe and the Japan Diabetes Optimal Treatment study for 3 major risk factors of cardiovascular diseases [J-DOIT3]), and in those with advanced microvascular complications (the Nephropathy In Diabetes-Type 2 [NID-2] study and Diabetic Nephropathy Remission and Regression Team Trial in Japan [DNETT-Japan]). Thus far, multifactorial intervention led to a reduction in cardiovascular and renal events, albeit not necessarily significant. It should be noted that not only baseline characteristics but also the control status of the risk factors and event rates during intervention among the patients widely varied from one trial to the next. Further evidence is needed for the efficacy of multifactorial intervention in a longer duration and in younger or elderly patients. Moreover, now that new classes of antidiabetic drugs are available, it should be addressed whether strict and safe glycemic control, alongside control of other risk factors, could lead to further risk reductions in micro- and macrovascular complications, thereby decreasing all-cause mortality in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by  
  • Exploring mechanisms underlying diabetes comorbidities and strategies to prevent vascular complications
    Takayoshi Sasako
    Diabetology International.2024; 15(1): 34.     CrossRef
  • Targeting ERS-mitophagy in hippocampal neurons to explore the improvement of memory by tea polyphenols in aged type 2 diabetic rats
    Wenjuan Feng, Chenhui Lv, Le Cheng, Xin Song, Xuemin Li, Haoran Xie, Shuangzhi Chen, Xi Wang, Lushan Xue, Cheng Zhang, Jie Kou, Lili Wang, Haifeng Zhao
    Free Radical Biology and Medicine.2024; 213: 293.     CrossRef
  • Risk of Dementia Among Patients With Diabetes in a Multidisciplinary, Primary Care Management Program
    Kailu Wang, Shi Zhao, Eric Kam-Pui Lee, Susan Zi-May Yau, Yushan Wu, Chi-Tim Hung, Eng-Kiong Yeoh
    JAMA Network Open.2024; 7(2): e2355733.     CrossRef
  • Causes of In-Hospital Death and Pharmaceutical Associations with Age of Death during a 10-Year Period (2011–2020) in Individuals with and without Diabetes at a Japanese Community General Hospital
    Minae Hosoki, Taiki Hori, Yousuke Kaneko, Kensuke Mori, Saya Yasui, Seijiro Tsuji, Hiroki Yamagami, Saki Kawata, Tomoyo Hara, Shiho Masuda, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsur
    Journal of Clinical Medicine.2024; 13(5): 1283.     CrossRef
  • External validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance
    Camilla Sammut-Powell, Rose Sisk, Ruben Silva-Tinoco, Gustavo de la Pena, Paloma Almeda-Valdes, Sonia Citlali Juarez Comboni, Susana Goncalves, Rory Cameron
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Gut Microbiota Targeted Approach by Natural Products in Diabetes Management: An Overview
    Priyanka Sati, Praveen Dhyani, Eshita Sharma, Dharam Chand Attri, Arvind Jantwal, Rajni Devi, Daniela Calina, Javad Sharifi-Rad
    Current Nutrition Reports.2024; 13(2): 166.     CrossRef
  • Lipids as potential mediators linking body mass index to diabetes: evidence from a mediation analysis based on the NAGALA cohort
    Song Lu, Qun Wang, Hengcheng Lu, Maobin Kuang, Min Zhang, Guotai Sheng, Yang Zou, Xiaoping Peng
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics
    Shuai Li, Zilong Song, Chunxiang Fan, Weiwei Zhang, Tianyi Ma, Xu Li, Qi Zhang, Ming Zhao, Tianfei Yu, Shanshan Li
    Biochemical Pharmacology.2024; 225: 116306.     CrossRef
  • Exploring mechanisms of insulin action and strategies to treat diabetes
    Takayoshi Sasako
    Endocrine Journal.2024; 71(7): 651.     CrossRef
  • Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
    Alfredo Caturano, Raffaele Galiero, Maria Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Davide Nilo, Giovanni Di Lorenzo, Celestino Sardu, Erica Vetrano, Marcellino Monda, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso
    Biomedicines.2024; 12(9): 2039.     CrossRef
  • The gaps between the guidelines definitions and routine of care adopted in primary health care regarding diabetes kidney disease: a real-life study
    Silvia Ferreira Bortoto, Jacira Xavier de Carvalho, Mozania Reis de Matos, Cristiane das Graças Dias Cavalcante, Elenilda Almeida Silva Andrade, Márcia Silva Queiroz
    Journal of Public Health.2024;[Epub]     CrossRef
  • Recent Glycemia Is a Major Determinant of β-Cell Function in Type 2 Diabetes Mellitus
    Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2024; 48(6): 1135.     CrossRef
  • Cardiovascular Risk Reduction in Type 2 Diabetes: Further Insights into the Power of Weight Loss and Exercise
    Seung-Hwan Lee
    Endocrinology and Metabolism.2023; 38(3): 302.     CrossRef
  • Sarcopenia: Loss of mighty armor against frailty and aging
    Takayoshi Sasako, Kohjiro Ueki
    Journal of Diabetes Investigation.2023; 14(10): 1145.     CrossRef
Original Articles
Metabolic Risk/Epidemiology
Article image
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Metab J. 2023;47(2):220-231.   Published online January 12, 2023
DOI: https://doi.org/10.4093/dmj.2021.0327
  • 65,535 View
  • 323 Download
  • 14 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We investigated whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an elevated risk of all-cause and cardiovascular mortality using a large-scale health examination cohort.
Methods
A total of 394,835 subjects in the Kangbuk Samsung Health Study cohort were enrolled from 2002 to 2012. Participants were categorized by the presence of nonalcoholic fatty liver disease (NAFLD) and MAFLD as follows: normal subjects; patients with both NAFLD and MAFLD; patients with NAFLD only; and patients with MAFLD only. Cox proportional hazards models were used to analyze the risk of mortality.
Results
During a median 5.7 years of follow-up, 20.69% was patients with both NAFLD and MAFLD, 1.51% was patients with NAFLD only, and 4.29% was patients with MAFLD only. All-cause and cardiovascular death was higher in patients with MAFLD than those without MAFLD (P<0.001, respectively). In patients with MAFLD only, the hazard ratio (HR) of all-cause and cardiovascular death was 1.35 (95% confidence interval [CI], 1.13 to 1.60) and 1.90 (95% CI, 1.26 to 2.88) after adjusting for age, which lost its statistical significance by multivariable adjustments. Compared to patients with less than two components of metabolic dysfunction, patients with more than two components of metabolic dysfunction were a higher risk of cardiovascular death (HR, 2.05; 95% CI, 1.25 to 3.38) and only women with more than two components of metabolic dysfunction were a higher risk of all-cause death (HR, 1.44; 95% CI, 1.02 to 2.03).
Conclusion
MAFLD criteria could identify a high-risk group for all-cause and cardiovascular death.

Citations

Citations to this article as recorded by  
  • Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
    Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
    Metabolism.2024; 152: 155789.     CrossRef
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Sex differences in mortality and liver‐related events in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
    Huimin Zhou, Haiyan Chen, Hanxiao Lu, Bo Wu, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang
    Liver International.2024; 44(7): 1600.     CrossRef
  • Association between dietary carbohydrate to fiber ratio and metabolic dysfunction associated fatty liver disease in adults: evidence from the NHANES 2017–2020
    Zhenmin Liu, Taiyong Fang
    Journal of Health, Population and Nutrition.2024;[Epub]     CrossRef
  • NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia
    Karl Vaz, William Kemp, Ammar Majeed, John Lubel, Dianna J. Magliano, Kristen M. Glenister, Lisa Bourke, David Simmons, Stuart K. Roberts
    Hepatology International.2024; 18(4): 1135.     CrossRef
  • Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies
    Grazia Pennisi, Giuseppe Infantino, Ciro Celsa, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Roberto Cannella, Carlo Ciccioli, Claudia La Mantia, Alessandro Mantovani, Francesco Mercurio, Herbert Tilg, Giovanni Targher, Vito Di Marco, Calogero Cammà, Sal
    Liver International.2024; 44(11): 2939.     CrossRef
  • Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and e
    Jae Hyun Bae
    Clinical and Molecular Hepatology.2024; 30(4): 665.     CrossRef
  • Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis
    Ghazala S Virk, Jaahnavi Vajje, Nausheen K Virk, Raam Mannam, Wajeeh Rehman, Naglaa G Ghobriel , Irfan-ud-din Mian, Muhammad Usama
    Cureus.2023;[Epub]     CrossRef
  • Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study
    Zhi-Qin Xie, Hong-Xia Li, Bing-Kun Wang, Zhao-Ming Yang, Zi-Yu Zhang, Wen-Liang Tan, Wen-Xin Li, Qing-Bin Wang, Lei Yang, Hong-Kai Zhuang, Chen-Wei Tang, Chang-Zhen Shang, Ya-Jin Chen
    European Journal of Internal Medicine.2023; 110: 62.     CrossRef
  • Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
    Han Na Jung, Chang Hee Jung
    Diabetes & Metabolism Journal.2023; 47(2): 198.     CrossRef
  • Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
    Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
    Metabolism.2023; 145: 155612.     CrossRef
  • Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
    Karl Vaz, Daniel Clayton-Chubb, Ammar Majeed, John Lubel, David Simmons, William Kemp, Stuart K. Roberts
    Hepatology International.2023; 17(5): 1082.     CrossRef
  • Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh
    Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289.     CrossRef
Cardiovascular Risk/Epidemiology
Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
You-Bin Lee, Minji Koo, Eunjin Noh, Soon Young Hwang, Jung A Kim, Eun Roh, So-hyeon Hong, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
Diabetes Metab J. 2022;46(5):722-732.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0225
  • 8,352 View
  • 357 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We assessed the myocardial infarction (MI), stroke, and all-cause death risks during follow-up according to the low-density lipoprotein cholesterol (LDL-C) levels among older adults.
Methods
The Korean National Health Insurance Service datasets (2002 to 2020) were used for this population-based cohort study. The hazards of MI, stroke, and all-cause mortality during follow-up were analyzed according to LDL-C level in individuals aged ≥65 years without baseline cardiovascular diseases (n=1,391,616).
Results
During a mean 7.55 years, 52,753 MIs developed; 84,224 strokes occurred over a mean 7.47 years. After a mean 8.50 years, 233,963 died. A decrease in LDL-C was associated with lower hazards of MI and stroke. The decreased hazard of stroke in lower LDL-C was more pronounced in statin users, and individuals with diabetes or obesity. The hazard of all-cause death during follow-up showed an inverted J-shaped pattern according to the LDL-C levels. However, the paradoxically increased hazard of mortality during follow-up in lower LDL-C was attenuated in statin users and individuals with diabetes, hypertension, or obesity. In statin users, lower LDL-C was associated with a decreased hazard of mortality during follow-up.
Conclusion
Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.

Citations

Citations to this article as recorded by  
  • Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study
    Ji Eun Jun, In-Kyung Jeong, Kyu Jeong Ahn, Ho Yeon Chung, You-Cheol Hwang
    European Journal of Preventive Cardiology.2024; 31(10): 1205.     CrossRef
  • Associations of Low-density Lipoprotein Cholesterol With All-cause and Cause-specific Mortality in Older Adults in China
    Wenqing Ni, Yuebin Lv, Xueli Yuan, Yan Zhang, Hongmin Zhang, Yijing Zheng, Xiaoming Shi, Jian Xu
    The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • Risk Factors of Acute Ischemic Stroke and Mortality Among Adults With Endocardial Fibroelastosis
    Talal Warsi, Kamleshun Ramphul, Mansimran Singh Dulay, Saddam Jeelani, Renuka Verma, Nomesh Kumar, Jasninder Singh Dhaliwal, Caleb Carver, Hemamalini Sakthivel, Syed Khurram Mushtaq Gardezi, Saurabh Deshpande, Akil A. Sherif, Alexander Liu, Raheel Ahmed
    The Neurologist.2024; 29(6): 317.     CrossRef
  • A Look at Primary and Secondary Prevention in the Elderly: The Two Sides of the Same Coin
    Maurizio Giuseppe Abrignani, Fabiana Lucà, Vincenzo Abrignani, Giuseppe Pelaggi, Alessandro Aiello, Furio Colivicchi, Francesco Fattirolli, Michele Massimo Gulizia, Federico Nardi, Paolo Giuseppe Pino, Iris Parrini, Carmelo Massimiliano Rao
    Journal of Clinical Medicine.2024; 13(15): 4350.     CrossRef
  • Contradictions in traditional ideas about atherosclerosis and the efficacy of lipid-lowering therapy. Promising directions
    A. P. Vasiliev, N. N. Streltsova
    Сибирский научный медицинский журнал.2024; 44(4): 38.     CrossRef
  • The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study
    Chin-Huan Chang, Shu-Tin Yeh, Seng-Wei Ooi, Chung-Yi Li, Hua-Fen Chen
    PeerJ.2023; 11: e14609.     CrossRef
  • ERCC1 polymorphism and its expression associated with ischemic stroke in Chinese population
    Xiao-Dong Deng, Jian-Lin Ke, Tai-Yu Chen, Qin Gao, Zhuo-Lin Zhao, Wei Zhang, Huan Liu, Ming-Liang Xiang, Li-Zhen Wang, Ying Ma, Yun Liu
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
    Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
  • Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
    Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
    Endocrinology and Metabolism.2022; 37(5): 759.     CrossRef
Brief Reports
Complications
Article image
Trends in the Incidence, Prevalence, and Mortality of End-Stage Kidney Disease in South Korea
Min-Jeong Lee, Kyoung Hwa Ha, Dae Jung Kim, Inwhee Park
Diabetes Metab J. 2020;44(6):933-937.   Published online December 23, 2020
DOI: https://doi.org/10.4093/dmj.2020.0156
  • 7,037 View
  • 263 Download
  • 17 Web of Science
  • 18 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Knowledge of the epidemiologic characteristics of end-stage kidney disease (ESKD) patients is essential. The trends in the prevalence, incidence, and mortality rates of ESKD were analyzed retrospectively using the Korean National Health Insurance ServiceNational Sample Cohort database between 2006 and 2015. From 2006 to 2015, the incidence of ESKD decreased from 28.6 to 24.0 per 100,000 people and showed a decreasing pattern with or without diabetes mellitus. However, the incidence of those aged ≥75 years increased, as did the mean age at the onset of ESKD. From 2007 to 2015, the prevalence of ESKD increased in all age groups, but particularly in those aged ≥75 years. The prevalence of ESKD differed by sex and diabetes mellitus status and this gap widened over time. Mortality rates in ESKD patients remained relatively constant throughout the study period. However, mortality rates in ESKD without diabetes decreased over the same period.

Citations

Citations to this article as recorded by  
  • Kidney Health Plan 2033 in Korea: bridging the gap between the present and the future
    Do Hyoung Kim, Young Youl Hyun, Jin Joo Cha, Sua Lee, Hyun Kyung Lee, Jong Wook Choi, Su-Hyun Kim, Sang Youb Han, Cheol Whee Park, Eun Young Lee, Dae Ryong Cha, Sung Gyun Kim, Chun Soo Lim, Sun-Hee Park
    Kidney Research and Clinical Practice.2024; 43(1): 8.     CrossRef
  • Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study
    Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Diabetes Research and Clinical Practice.2024; 210: 111639.     CrossRef
  • Effects of Kt/Vurea on outcomes according to age in patients on maintenance hemodialysis
    Junseok Jeon, Gui Ok Kim, Bo Yeon Kim, Eun Jung Son, Jun Young Do, Jung Eun Lee, Seok Hui Kang
    Clinical Kidney Journal.2024;[Epub]     CrossRef
  • 2023 Diabetic Kidney Disease Fact Sheet in Korea
    Nam Hoon Kim, Mi-Hae Seo, Jin Hyung Jung, Kyung Do Han, Mi Kyung Kim, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(3): 463.     CrossRef
  • Clinical Validation of a Mobile-Based ACR (Urine Albumin-to-Creatinine Ratio) Test Kit: Comparative Analysis with Benchtop Devices
    Jiwon RYU, Eung-Kyu PARK, JunHyuck JANG, Dong-Hoon LEE
    Korean Journal of Health Promotion.2024; 24(3): 118.     CrossRef
  • Kidney replacement therapy trends in end-stage kidney disease patients in South Korea during the COVID-19 pandemic
    Ah-Young Kim, Min-Jeong Lee, Heejung Choi, Hankil Lee, Inwhee Park
    The Korean Journal of Internal Medicine.2024; 39(6): 967.     CrossRef
  • Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018
    Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585.     CrossRef
  • Usefulness of continuous glucose monitoring of blood glucose control in patients with diabetes undergoing hemodialysis: A pilot study
    Sua Lee, Soyoung Lee, Kyeong Min Kim, Jong Ho Shin
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Association between N-Terminal Prohormone Brain Natriuretic Peptide and Decreased Skeletal Muscle Mass in a Healthy Adult Population: A Cross-Sectional Study
    Tae Kyung Yoo, Marie Yung-Chen Wu, Moon Soo Kim, Mi-Yeon Lee, Yong-Taek Lee, Kyung Jae Yoon, Chul-Hyun Park
    Endocrinology and Metabolism.2023; 38(2): 269.     CrossRef
  • Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Sun Ok Song, Eugene Han, Kang Ju Son, Bong-Soo Cha, Byung-Wan Lee
    Journal of Clinical Medicine.2023; 12(9): 3160.     CrossRef
  • Epigenome-wide association study of diabetic chronic kidney disease progression in the Korean population: the KNOW-CKD study
    Hye Youn Sung, Sangjun Lee, Miyeun Han, Woo Ju An, Hyunjin Ryu, Eunjeong Kang, Yong Seek Park, Seung Eun Lee, Curie Ahn, Kook-Hwan Oh, Sue K. Park, Jung-Hyuck Ahn
    Scientific Reports.2023;[Epub]     CrossRef
  • Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
    Kieran F. Docherty, Inder S. Anand, Chern-En Chiang, Vijay K. Chopra, Akshay S. Desai, Masafumi Kitakaze, Subodh Verma, Pham N. Vinh, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabat
    JACC: Asia.2022; 2(2): 139.     CrossRef
  • Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
    Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
    The Korean Journal of Internal Medicine.2022; 37(3): 502.     CrossRef
  • The risk of Parkinson's disease according to diabetic kidney disease status in a Korean population
    Seung Eun Lee, Juhwan Yoo, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
    Parkinsonism & Related Disorders.2022; 100: 13.     CrossRef
  • Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
    Nam Hoon Kim, Nan Hee Kim
    Diabetes & Metabolism Journal.2022; 46(4): 543.     CrossRef
  • The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study
    Jun Hyoung Kim, Heeseon Jang, Jung Ho Kim, Joon Young Song, Shin-Woo Kim, Sang Il Kim, Bo Youl Choi, Jun Yong Choi
    Infection & Chemotherapy.2022; 54(3): 534.     CrossRef
  • Sex difference in the association among nutrition, muscle mass, and strength in peritoneal dialysis patients
    Jun Young Do, Seok Hui Kang
    Scientific Reports.2022;[Epub]     CrossRef
  • Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk
    Seohyun Kim, Gyuri Kim, Jae Hyeon Kim
    Scientific Reports.2022;[Epub]     CrossRef
Complications
Article image
Trends in Cardiovascular Complications and Mortality among Patients with Diabetes in South Korea
Jung Hwan Park, Kyoung Hwa Ha, Bo Yeon Kim, Jae Hyuk Lee, Dae Jung Kim
Diabetes Metab J. 2021;45(1):120-124.   Published online December 9, 2020
DOI: https://doi.org/10.4093/dmj.2020.0175
Correction in: Diabetes Metab J 2021;45(2):283
  • 13,156 View
  • 386 Download
  • 36 Web of Science
  • 41 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
We investigated the cardiovascular complications and mortality rates of patients with diabetes in South Korea. The rates of hospitalization due to cardiovascular complications and mortality were analyzed using the Korean National Health Insurance Service-National Sample Cohort. From 2006 to 2015, the rates of hospitalization due to major cardiovascular complications decreased, while those due to heart failure (from 72 to 146 and 124 to 161 per 10,000 men and women, respectively) and peripheral artery disease (from 39 to 55 and 19 to 35 per 10,000 men and women, respectively) increased. In the period 2007 to 2015, the mortality rates for cancer, cerebrovascular disease, diabetes, heart disease, and hypertensive disease all decreased. However, the mortality rate for pneumonia increased. We observed a continuous reduction in cardiovascular complications and mortality in adults with diabetes. However, with the increase in some diabetes complications, more efforts are needed to prevent diabetes complications.

Citations

Citations to this article as recorded by  
  • Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki
    PLOS ONE.2024; 19(2): e0299035.     CrossRef
  • Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study
    Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Diabetes Research and Clinical Practice.2024; 210: 111639.     CrossRef
  • The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
    Sushant Koirala, Michael Sunnaa, Thomas Bernier, Ahmet Afsin Oktay
    Current Cardiology Reports.2024; 26(11): 1309.     CrossRef
  • Baicalin attenuates vascular inflammation and endothelial dysfunction in diabetes
    Lingchao Miao, Yifan Yang, Jinming Dai, Mei Bai, Yuehan Wang, Haiying Cui, Lin Lin, Metab Alharbi, Wai San Cheang
    Food Frontiers.2024; 5(6): 2756.     CrossRef
  • Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
    Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
    Journal of Diabetes Investigation.2024;[Epub]     CrossRef
  • Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
    Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
    Diabetes & Metabolism Journal.2024; 48(6): 1084.     CrossRef
  • Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century
    Peter A. Lazzarini, Susanna M. Cramb, Jonathan Golledge, Jedidiah I. Morton, Dianna J. Magliano, Jaap J. Van Netten
    Diabetologia.2023; 66(2): 267.     CrossRef
  • Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England
    Suping Ling, Francesco Zaccardi, Eyad Issa, Melanie J. Davies, Kamlesh Khunti, Karen Brown
    Diabetologia.2023; 66(4): 657.     CrossRef
  • Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Journal of Lipid and Atherosclerosis.2023; 12(1): 12.     CrossRef
  • Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
    Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
    International Journal of Heart Failure.2023; 5(1): 1.     CrossRef
  • Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
    Dae Jung Kim, Wayne H‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino
    Journal of Diabetes Investigation.2023; 14(3): 417.     CrossRef
  • Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 1.     CrossRef
  • Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
    Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 10.     CrossRef
  • The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study
    Seung Eun Lee, Juhwan Yoo, Bong-Seong Kim, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey
    Jong Ha Baek, Yong-Moon Park, Kyung Do Han, Min Kyong Moon, Jong Han Choi, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2023; 47(2): 201.     CrossRef
  • Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
    Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
    BMC Public Health.2023;[Epub]     CrossRef
  • The Present and Future of Artificial Intelligence-Based Medical Image in Diabetes Mellitus: Focus on Analytical Methods and Limitations of Clinical Use
    Ji-Won Chun, Hun-Sung Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • The Role of Echocardiography in Evaluating Cardiovascular Diseases in Patients with Diabetes Mellitus
    Sun Hwa Lee, Jae-Hyeong Park
    Diabetes & Metabolism Journal.2023; 47(4): 470.     CrossRef
  • Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea
    Ji Hye Huh, Serim Kwon, Gui Ok Kim, Bo Yeon Kim, Kyoung Hwa Ha, Dae Jung Kim
    Diabetes Care.2023; 46(9): 1700.     CrossRef
  • Management of Dyslipidemia in Patients with Diabetes Mellitus
    Kyung Ae Lee
    The Journal of Korean Diabetes.2023; 24(3): 111.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
    Ye Seul Yang
    The Journal of Korean Diabetes.2023; 24(3): 135.     CrossRef
  • Interpreting global trends in type 2 diabetes complications and mortality
    Mohammed K. Ali, Jonathan Pearson-Stuttard, Elizabeth Selvin, Edward W. Gregg
    Diabetologia.2022; 65(1): 3.     CrossRef
  • Cardiovascular disease in patients with type 2 diabetes
    Ja Young Jeon, Dae Jung Kim
    Journal of Diabetes Investigation.2022; 13(4): 614.     CrossRef
  • Effects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
    Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
    Cardiovascular Prevention and Pharmacotherapy.2022; 4(1): 42.     CrossRef
  • Editorial: Management of Diabetes and its Complications: A Focus on Endothelial Dysfunction
    Shanhu Qiu, Jianhua Ma, Tongzhi Wu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Smoking, Metabolic Syndrome, and Cardiovascular Disease
    Seo Young Kang
    Korean Journal of Family Practice.2022; 12(2): 59.     CrossRef
  • Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
    Cheng-Xu Ma, Xiao-Ni Ma, Cong-Hui Guan, Ying-Dong Li, Dídac Mauricio, Song-Bo Fu
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study
    Jae‐Seung Yun, Kyungdo Han, Yong‐Moon Park, Eugene Han, Yong‐ho Lee, Seung‐Hyun Ko
    Journal of Diabetes Investigation.2022; 13(9): 1533.     CrossRef
  • Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
    Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sung
    Diabetes & Metabolism Journal.2022; 46(3): 464.     CrossRef
  • Diabetes Fact Sheet in Korea 2021
    Jae Hyun Bae, Kyung-Do Han, Seung-Hyun Ko, Ye Seul Yang, Jong Han Choi, Kyung Mook Choi, Hyuk-Sang Kwon, Kyu Chang Won
    Diabetes & Metabolism Journal.2022; 46(3): 417.     CrossRef
  • Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus
    Jeongmin Lee, Jae-Seung Yun, Seung-Hyun Ko
    Nutrients.2022; 14(15): 3086.     CrossRef
  • Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
    Nam Hoon Kim, Nan Hee Kim
    Diabetes & Metabolism Journal.2022; 46(4): 543.     CrossRef
  • Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes
    Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu
    Diabetes Research and Clinical Practice.2022; 191: 110067.     CrossRef
  • Blood Pressure Target in Type 2 Diabetes Mellitus
    Hyun-Jin Kim, Kwang-il Kim
    Diabetes & Metabolism Journal.2022; 46(5): 667.     CrossRef
  • Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Metabolism.2022; 137: 155327.     CrossRef
  • Trends in diabetes-related complications in Singapore, 2013–2020: A registry-based study
    Joshua Kuan Tan, Nur Nasyitah Mohamed Salim, Gek Hsiang Lim, Sing Yi Chia, Julian Thumboo, Yong Mong Bee, Ferdinando Carlo Sasso
    PLOS ONE.2022; 17(10): e0275920.     CrossRef
  • Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
    Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
    Endocrinology and Metabolism.2022; 37(5): 759.     CrossRef
  • Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes
    Seon-Ah Cha, Jae-Seung Yun, Gee-Hee Kim, Yu-Bae Ahn
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Heart Failure and Diabetes Mellitus: Dangerous Liaisons
    Hae-Young Lee
    International Journal of Heart Failure.2022; 4(4): 163.     CrossRef
  • Diabetes and Stroke
    Junghyun Noh
    The Journal of Korean Diabetes.2021; 22(1): 26.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
Original Articles
COVID-19
Article image
Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study
Sun Joon Moon, Eun-Jung Rhee, Jin-Hyung Jung, Kyung-Do Han, Sung-Rae Kim, Won-Young Lee, Kun-Ho Yoon
Diabetes Metab J. 2020;44(5):737-746.   Published online October 21, 2020
DOI: https://doi.org/10.4093/dmj.2020.0141
  • 11,703 View
  • 209 Download
  • 26 Web of Science
  • 25 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Inconsistent results have been observed regarding the independent effect of diabetes on the severity of coronavirus disease 2019 (COVID-19). We conducted a nationwide population-based cohort study to evaluate the relationship between diabetes and COVID-19 severity in South Korea.
Methods
Patients with laboratory-confirmed COVID-19 aged ≥30 years were enrolled and medical claims data were obtained from the Korean Health Insurance Review and Assessment Service. Hospitalization, oxygen treatment, ventilator application, and mortality were assessed as severity outcomes. Multivariate logistic regression analyses were performed after adjusting for age, sex, and comorbidities.
Results
Of 5,307 COVID-19 patients, the mean age was 56.0±14.4 years, 2,043 (38.5%) were male, and 770 (14.5%) had diabetes. The number of patients who were hospitalized, who received oxygen, who required ventilator support, and who died was 4,986 (94.0%), 884 (16.7%), 121 (2.3%), and 211 (4.0%), respectively. The proportion of patients with diabetes in the abovementioned outcome groups was 14.7%, 28.1%, 41.3%, 44.6%, showing an increasing trend according to outcome severity. In multivariate analyses, diabetes was associated with worse outcomes, with an adjusted odds ratio (aOR) of 1.349 (95% confidence interval [CI], 1.099 to 1.656; P=0.004) for oxygen treatment, an aOR of 1.930 (95% CI, 1.276 to 2.915; P<0.001) for ventilator use, and an aOR of 2.659 (95% CI, 1.896 to 3.729; P<0.001) for mortality.
Conclusion
Diabetes was associated with worse clinical outcomes in Korean patients with COVID-19, independent of other comorbidities. Therefore, patients with diabetes and COVID-19 should be treated with caution.

Citations

Citations to this article as recorded by  
  • Reasons for Hospitalization Among Australians With Type 1 or Type 2 Diabetes and COVID-19
    Dunya Tomic, Jonathan E. Shaw, Dianna J. Magliano
    Canadian Journal of Diabetes.2024; 48(1): 53.     CrossRef
  • Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium
    Thomas Servais, France Laurent, Thomas Roland, Camelia Rossi, Elodie De Groote, Valérie Godart, Ernestina Repetto, Michel Ponchon, Pascale Chasseur, Laurent Crenier, Sandrine Van Eeckhoudt, John Yango, Philippe Oriot, Mirela Morisca Gavriliu, Stéphanie Ro
    Annales d'Endocrinologie.2024; 85(1): 36.     CrossRef
  • Factors Associated with Length of Hospitalization in Patients with Diabetes and Mild COVID-19: Experiences from a Tertiary University Center in Serbia
    Vojislav M. Ciric, Natasa Krsto Rancic, Milica M. Pesic, Danijela B. Radojkovic, Nikola Milenkovic
    Medicina.2024; 60(5): 788.     CrossRef
  • Association of ABO genetic Polymorphisms and Type 2 Diabetes Mellitus Susceptibility in the Korean Population
    Yu-Na Kim, Sung Won Lee, Sangwook Park
    Biomedical Science Letters.2024; 30(2): 65.     CrossRef
  • Impact of COVID-19 on the Microbiome and Inflammatory Status of Type 2 Diabetes Patients
    Gratiela Gradisteanu Pircalabioru, Georgiana Alexandra Grigore, Ilda Czobor Barbu, Mariana-Carmen Chifiriuc, Octavian Savu
    Biomedicines.2023; 11(1): 179.     CrossRef
  • Bidirectional Relationship between Glycemic Control and COVID-19 and Perspectives of Islet Organoid Models of SARS-CoV-2 Infection
    Tongran Zhang, Nannan Wang, Lingqiang Zhu, Lihua Chen, Huisheng Liu
    Biomedicines.2023; 11(3): 856.     CrossRef
  • Anti-SARS-CoV-2 antibody levels predict outcome in COVID-19 patients with type 2 diabetes: a prospective cohort study
    Sylvia Mink, Christoph H. Saely, Andreas Leiherer, Matthias Frick, Thomas Plattner, Heinz Drexel, Peter Fraunberger
    Scientific Reports.2023;[Epub]     CrossRef
  • Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations
    Dan Ziegler, Solomon Tesfaye, Vincenza Spallone, Irina Gurieva, Juma Al Kaabi, Boris Mankovsky, Emil Martinka, Gabriela Radulian, Khue Thy Nguyen, Alin O Stirban, Tsvetalina Tankova, Tamás Varkonyi, Roy Freeman, Péter Kempler, Andrew JM Boulton
    Diabetes Research and Clinical Practice.2022; 186: 109063.     CrossRef
  • The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
    Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • The Interrelationship between Diabetes Mellitus and COVID-19
    Thekra Abdulaali Abed, Zainab Adil Ghani Chabuck
    Medical Journal of Babylon.2022; 19(1): 1.     CrossRef
  • Impact of Type 2 Diabetes Mellitus on the Incidence and Outcomes of COVID-19 Needing Hospital Admission According to Sex: Retrospective Cohort Study Using Hospital Discharge Data in Spain, Year 2020
    Jose M. de Miguel-Yanes, Rodrigo Jimenez-Garcia, Javier de Miguel-Diez, Valentin Hernández-Barrera, David Carabantes-Alarcon, Jose J. Zamorano-Leon, Ricardo Omaña-Palanco, Ana Lopez-de-Andres
    Journal of Clinical Medicine.2022; 11(9): 2654.     CrossRef
  • Diabetes Fact Sheet in Korea 2021
    Jae Hyun Bae, Kyung-Do Han, Seung-Hyun Ko, Ye Seul Yang, Jong Han Choi, Kyung Mook Choi, Hyuk-Sang Kwon, Kyu Chang Won
    Diabetes & Metabolism Journal.2022; 46(3): 417.     CrossRef
  • The burden and risks of emerging complications of diabetes mellitus
    Dunya Tomic, Jonathan E. Shaw, Dianna J. Magliano
    Nature Reviews Endocrinology.2022; 18(9): 525.     CrossRef
  • Clinical Characteristics and Outcomes of Patients Hospitalized with COVID-19 at Case Hospital, Uganda
    Mirriam Apiyo, Ronald Olum, Amina Kabuye, Betty Khainza, Anne M. Amate, Vittal Byabashaija, Derrick Nomujuni, Kato Sebbaale, Peter Senfuka, Simon Kazibwe, Gurav Sharma, Lindsay Davidson, Felix Bongomin, Diamantis Kofteridis
    Interdisciplinary Perspectives on Infectious Diseases.2022; 2022: 1.     CrossRef
  • Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
    Daniel J. Drucker
    Cell Metabolism.2021; 33(3): 479.     CrossRef
  • Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
    Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
    Diabetes & Metabolism Journal.2021; 45(2): 251.     CrossRef
  • COVID-19 vaccine acceptance among high-risk populations in Uganda
    Felix Bongomin, Ronald Olum, Irene Andia-Biraro, Frederick Nelson Nakwagala, Khalid Hudow Hassan, Dianah Rhoda Nassozi, Mark Kaddumukasa, Pauline Byakika-Kibwika, Sarah Kiguli, Bruce J. Kirenga
    Therapeutic Advances in Infectious Disease.2021;[Epub]     CrossRef
  • Caracterización clínica, según niveles de glucemia, de pacientes hospitalizados por COVID-19: serie de casos
    Irene Stulin, Maria Montes de Oca, Gabriela Blanco, Laura Sánchez, Isabel-Carlota Silva, Jennireth Quevedo, Maria Cristina Arvelo, Nathalia Valera, Irene Papa, Hospital Centro Médico de Caracas, Caracas, Venezuela Bacci, Fátima de Abreu, Héctor Villarroel
    Investigación Clínica.2021; 62: 27.     CrossRef
  • COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
    Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
  • Diabetes Mellitus and COVID-19: Review Article
    Mahmoud Nassar, Ahmed Daoud, Nso Nso, Luis Medina, Victoria Ghernautan, Harangad Bhangoo, Andrew Nyein, Mahmoud Mohamed, Ahmed Alqassieh, Karim Soliman, Mostafa Alfishawy, Issac Sachmechi, Anoop Misra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(6): 102268.     CrossRef
  • Dissection of non-pharmaceutical interventions implemented by Iran, South Korea, and Turkey in the fight against COVID-19 pandemic
    Mohammad Keykhaei, Sogol Koolaji, Esmaeil Mohammadi, Reyhaneh Kalantar, Sahar Saeedi Moghaddam, Arya Aminorroaya, Shaghayegh Zokaei, Sina Azadnajafabad, Negar Rezaei, Erfan Ghasemi, Nazila Rezaei, Rosa Haghshenas, Yosef Farzi, Sina Rashedi, Bagher Larijan
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1919.     CrossRef
  • A Systematic Review and Meta-analysis of Diabetes Associated Mortality in Patients with COVID-19
    Puneeta Gupta, Meeta Gupta, Neena KAtoch, Ketan Garg, Bhawna Garg
    International Journal of Endocrinology and Metabolism.2021;[Epub]     CrossRef
  • Diabetes, Obesity, and COVID-19
    Sang Youl Rhee
    The Journal of Korean Diabetes.2021; 22(3): 174.     CrossRef
  • Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
    Yahya Mahamat-Saleh, Thibault Fiolet, Mathieu Edouard Rebeaud, Matthieu Mulot, Anthony Guihur, Douae El Fatouhi, Nasser Laouali, Nathan Peiffer-Smadja, Dagfinn Aune, Gianluca Severi
    BMJ Open.2021; 11(10): e052777.     CrossRef
  • Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide-Cohort Study (Diabetes Metab J 2020;44:737-46)
    Kyuho Kim, Tae Jung Oh
    Diabetes & Metabolism Journal.2020; 44(6): 938.     CrossRef
Covid-19
Article image
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea
Mi Kyung Kim, Jae-Han Jeon, Sung-Woo Kim, Jun Sung Moon, Nan Hee Cho, Eugene Han, Ji Hong You, Ji Yeon Lee, Miri Hyun, Jae Seok Park, Yong Shik Kwon, Yeon-Kyung Choi, Ki Tae Kwon, Shin Yup Lee, Eon Ju Jeon, Jin-Woo Kim, Hyo-Lim Hong, Hyun Hee Kwon, Chi Young Jung, Yin Young Lee, Eunyeoung Ha, Seung Min Chung, Jian Hur, June Hong Ahn, Na-young Kim, Shin-Woo Kim, Hyun Ha Chang, Yong Hoon Lee, Jaehee Lee, Keun-Gyu Park, Hyun Ah Kim, Ji-Hyun Lee
Diabetes Metab J. 2020;44(4):602-613.   Published online August 12, 2020
DOI: https://doi.org/10.4093/dmj.2020.0146
  • 14,845 View
  • 219 Download
  • 71 Web of Science
  • 83 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than eight million people worldwide by June 2020. Given the importance of the presence of diabetes mellitus (DM) for host immunity, we retrospectively evaluated the clinical characteristics and outcomes of moderate-to-severe COVID-19 in patients with diabetes.

Methods

We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease. The demographic, laboratory, and radiologic findings, and the mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM. In addition, 1:1 propensity score (PS)-matching was conducted with the DM group.

Results

Compared with the non-DM group (n=847), patients with DM (n=235) were older, exhibited higher mortality, and required more intensive care. Even after PS-matching, patients with DM exhibited more severe disease, and DM remained a prognostic factor for higher mortality (hazard ratio, 2.40; 95% confidence interval, 1.38 to 4.15). Subgroup analysis revealed that the presence of DM was associated with higher mortality, especially in older people (≥70 years old). Prior use of a dipeptidyl peptidase-4 inhibitor or a renin-angiotensin system inhibitor did not affect mortality or the clinical severity of the disease.

Conclusion

DM is a significant risk factor for COVID-19 severity and mortality. Our findings imply that COVID-19 patients with DM, especially if elderly, require special attention and prompt intensive care.

Citations

Citations to this article as recorded by  
  • Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
    Carmen Tisch, Eleni Xourgia, Aristomenis Exadaktylos, Mairi Ziaka
    Endocrine.2024; 85(2): 660.     CrossRef
  • Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19
    Łukasz Lewandowski, Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, Dorota Bednarska-Chabowska, Joanna Adamiec-Mroczek, Adrian Doroszko, Małgorzata Trocha, Krzysztof Kujawa, Agnieszka Matera-Witkiewicz, Edwin Kuźnik, Paweł Lubieniecki, Marcin Madziarski
    Biomedicines.2024; 12(3): 605.     CrossRef
  • Prognostic Value of Hyperglycemia and Insulin Resistance Among Patients with Confirmed COVID-19 Infections at Admission to the Alexandria Fever Hospital, Egypt
    Fathy Z. Alsewy, Magdy H. Megallaa, Salma A. Imbaby, Huda M. Zidan, Heba S. Kassab, Mai H. Badrah
    Metabolic Syndrome and Related Disorders.2024; 22(7): 551.     CrossRef
  • The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
    Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang
    Therapeutic Innovation & Regulatory Science.2024; 58(4): 773.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus
    D. V. Belikina, T. A. Nekrasova, L. G. Strongin, E. M. Durygina, M. Yu. Rodina
    FOCUS. Endocrinology.2024; 5(1): 20.     CrossRef
  • Research status and hotspots in the field of endoplasmic reticulum stress and liver disease: A bibliometric study
    Ruiyu Wang, Shu Huang, Ping Wang, Xiaowei Tang, Huan Xu, Wei Zhang, Lei Shi, Xiaolin Zhong, Muhan Lü, Xian Zhou, Xiaomin Shi
    Medicine.2024; 103(22): e38450.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
    Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
    Diabetes Research and Clinical Practice.2023; 195: 110205.     CrossRef
  • Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
    Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
    Diabetologia.2023; 66(8): 1395.     CrossRef
  • Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
    A. V. Alieva, A. A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Z. Khalilova, V. A. Talenova, N. U. Alimova, M. D. Aripova, A. S. Sadikova
    Obesity and metabolism.2023; 20(2): 92.     CrossRef
  • Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
    Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
    Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
  • Epidemiological features and consequences of COVID‐19 in patients with and without gastrointestinal symptoms in southwestern Iran. A retrospective observational study
    Habibollah Azarbakhsh, Leila Moftakhar, Aliasghar Valipour, Alireza Mirahmadizadeh, Hekmat Allah Moradi, Elahe Piraee
    Health Science Reports.2023;[Epub]     CrossRef
  • The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
    Yun-Ting Huang, Andrew Steptoe, Riyaz S. Patel, Esme Fuller Thomson, Dorina Cadar
    Gerontology.2023; 69(10): 1200.     CrossRef
  • Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
    Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
    Archives of Medical Research.2022; 53(2): 186.     CrossRef
  • Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
    Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
    Diabetes & Metabolism.2022; 48(1): 101307.     CrossRef
  • Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
    Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
    Primary Care Diabetes.2022; 16(1): 162.     CrossRef
  • Prevalence and impact of diabetes in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
    Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar
    Journal of Diabetes.2022; 14(2): 144.     CrossRef
  • Interplay between Inflammaging, Frailty and Nutrition in Covid-19: Preventive and Adjuvant Treatment Perspectives
    A. Padilha de Lima, M. Macedo Rogero, T. Araujo Viel, H.M. Garay-Malpartida, I. Aprahamian, Sandra Maria Lima Ribeiro
    The Journal of nutrition, health and aging.2022; 26(1): 67.     CrossRef
  • Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study
    Mi Seon Lee, Rosie Lee, Cheol Woo Ko, Jung Eun Moon
    Journal of Yeungnam Medical Science.2022; 39(1): 46.     CrossRef
  • Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network
    Qian Gao, Wenjun Zhang, Tingting Li, Guojun Yang, Wei Zhu, Naijun Chen, Huawei Jin
    Scientific Reports.2022;[Epub]     CrossRef
  • Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
    Afnan Alshnbari, Iskandar Idris
    Current Medical Research and Opinion.2022; 38(3): 357.     CrossRef
  • Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
    Li-Min Zhao, Xie-Hui Chen, Mei Qiu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • COVID-19 and Diabetes
    Awadhesh Kumar Singh, Kamlesh Khunti
    Annual Review of Medicine.2022; 73(1): 129.     CrossRef
  • The enzymes in COVID-19: A review
    Maria Helena Menezes Estevam Alves, Layla Carvalho Mahnke, Tifany Cerqueira Macedo, Thais Ketinly dos Santos Silva, Luiz Bezerra Carvalho Junior
    Biochimie.2022; 197: 38.     CrossRef
  • IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW
    Adnan A. Zainal, Marwan M. Merkhan
    Military Medical Science Letters.2022; 91(2): 140.     CrossRef
  • Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
    Adithan Ganesh, Michael D. Randall
    British Journal of Clinical Pharmacology.2022; 88(6): 2642.     CrossRef
  • Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
    Clifford J. Bailey, Mike Gwilt
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
    Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
    Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
    Metabolism.2022; 131: 155196.     CrossRef
  • Glucose-Lowering Agents and COVID-19
    Ah Reum Khang
    The Journal of Korean Diabetes.2022; 23(1): 1.     CrossRef
  • Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    Endocrinology, Diabetes & Metabolism.2022;[Epub]     CrossRef
  • The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
    Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
    Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • Diabetes and SARS-CoV-2–Is There a Mutual Connection?
    Anna P. Jedrzejak, Edyta K. Urbaniak, Jadwiga A. Wasko, Natalia Ziojla, Malgorzata Borowiak
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2022; 11: 729.     CrossRef
  • Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?
    Marzieh Rohani-Rasaf, Kosar Mirjalili, Akram Vatannejad, Maryam Teimouri, Xiao-Feng Yang
    PLOS ONE.2022; 17(8): e0272000.     CrossRef
  • Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
    Seong Ho Kim, Ji Young Kim, Eun Song Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Annals of Medicine.2022; 54(1): 2724.     CrossRef
  • Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
    Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
    World Journal of Virology.2022; 11(6): 399.     CrossRef
  • Prevalencia de secuelas en pacientes con diabetes mellitus tipo 2 sobrevivientes al COVID-19
    Gianela M. Cancino-Castillo, Miguel A. Tresierra-Ayala, Jorge L. Campos-Reyna, Jaime Rosales-Rimache
    REVISTA MÉDICA VALLEJIANA/ Vallejian Medical Journal.2022; 11(2): 48.     CrossRef
  • Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq
    Hussein Nafakhi, Mohammed Alareedh, Karrar Al-Buthabhak, Foaad Shaghee, Ahmed Nafakhi, Samet Kasim
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 33.     CrossRef
  • Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
    Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, Anoop Misra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 159.     CrossRef
  • COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis
    Mark Thomaz Ugliara Barone, Belinda Ngongo, Simone Bega Harnik, Lucas Xavier de Oliveira, Dániel Végh, Patrícia Vieira de Luca, Hermelinda Cordeiro Pedrosa, Franco Giraudo, Roque Cardona-Hernandez, Nayanjeet Chaudhury, Luiz Menna-Barreto
    Diabetes Research and Clinical Practice.2021; 171: 108587.     CrossRef
  • A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
    Chia Siang Kow, Syed Shahzad Hasan
    Therapies.2021; 76(4): 361.     CrossRef
  • Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
    B. M. Bonora, A. Avogaro, G. P. Fadini
    Journal of Endocrinological Investigation.2021; 44(7): 1379.     CrossRef
  • Prognostic bioindicators in severe COVID-19 patients
    L. Bergantini, E. Bargagli, M. d'Alessandro, R.M. Refini, P. Cameli, L. Galasso, C. Scapellato, F. Montagnani, S. Scolletta, F. Franchi, S. Valente, D. Bennett, G. Sebastiani, B. Frediani, F. Dotta
    Cytokine.2021; 141: 155455.     CrossRef
  • Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients
    Leila Moftakhar, Parisa Moftakhar, Elahe Piraee, Haleh Ghaem, Aliasghar Valipour, Habibollah Azarbakhsh
    International Journal of Diabetes in Developing Countries.2021; 41(3): 383.     CrossRef
  • DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
    André J. Scheen
    Diabetes & Metabolism.2021; 47(2): 101213.     CrossRef
  • Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
    Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, Deborah Ancelle, Sara Barraud, Lyse Bordier, Aurélie Carlier, Nicolas Chevalier, Christine Coffin‐Boutreux, Emmanuel Cosson, Anne Dorange, O
    Diabetes, Obesity and Metabolism.2021; 23(5): 1162.     CrossRef
  • Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
    Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay K. Bhadada
    Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub]     CrossRef
  • Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
    Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, Giovanni Corrao, Franz H. Messerli
    Journal of Hypertension.2021; 39(4): 784.     CrossRef
  • Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis
    Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Qingrong Sun, Yue Zhang, Xiaosheng Wang
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
    Timotius Ivan Hariyanto, Andree Kurniawan
    Journal of Diabetes & Metabolic Disorders.2021; 20(1): 543.     CrossRef
  • Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis
    Halla Kaminska, Lukasz Szarpak, Dariusz Kosior, Wojciech Wieczorek, Agnieszka Szarpak, Mahdi Al-Jeabory, Wladyslaw Gawel, Aleksandra Gasecka, Milosz J. Jaguszewski, Przemyslawa Jarosz-Chobot
    Acta Diabetologica.2021; 58(8): 1101.     CrossRef
  • Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
    Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, Henny Juliastuti, Eka Noneng Nawangsih, Arief Wibowo, Michael Anthonius Lim, Raymond Pranata
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(3): 777.     CrossRef
  • Post-infection depressive, anxiety and post-traumatic stress symptoms: A prospective cohort study in patients with mild COVID-19
    Flavia Ismael, João C.S. Bizario, Tatiane Battagin, Beatriz Zaramella, Fabio E. Leal, Julio Torales, Antonio Ventriglio, Megan E. Marziali, Silvia S. Martins, João M. Castaldelli-Maia
    Progress in Neuro-Psychopharmacology and Biological Psychiatry.2021; 111: 110341.     CrossRef
  • Managing diabetes in diabetic patients with COVID: where do we start from?
    Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
    Acta Diabetologica.2021; 58(11): 1441.     CrossRef
  • Is diabetes mellitus a wrongdoer to COVID-19 severity?
    Sanjib Sarkar, Dibyendu Das, Sawlang Borsingh Wann, Jatin Kalita, Prasenjit Manna
    Diabetes Research and Clinical Practice.2021; 178: 108936.     CrossRef
  • Dipeptidyl Peptidase 4 Inhibitor, an Update
    Ju Hee Lee
    The Journal of Korean Diabetes.2021; 22(2): 91.     CrossRef
  • Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19
    Zhenmu Jin, Mo Zheng, Jichan Shi, Xinchun Ye, Fang Cheng, Que-Lu Chen, Jianping Huang, Xian-Gao Jiang
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
    Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse, Tim Q. Duong
    Diabetes Care.2021; 44(7): 1564.     CrossRef
  • The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus
    Wenxing Yang, Xuehong Sun, Jun Zhang, Kui Zhang
    Diabetes Research and Clinical Practice.2021; 178: 108977.     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
    Jordan Loader, Erik Lampa, Stefan Gustafsson, Thomas Cars, Johan Sundström
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus
    Ayça Elibol, Didem Eren, Macide Deniz Erdoğan, Merve Elmaağaç, Oguzhan Sıtkı Dizdar, İlhami Çelik, Ali İhsan Günal
    Primary Care Diabetes.2021; 15(5): 806.     CrossRef
  • Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors
    Melina Farshbafnadi, Sara Kamali Zonouzi, Mohammadmahdi Sabahi, Mahsa Dolatshahi, Mohammad Hadi Aarabi
    Experimental Gerontology.2021; 154: 111507.     CrossRef
  • Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology
    Moudhi Almutlaq, Abir Abdullah Alamro, Fayhan Alroqi, Tlili Barhoumi
    CJC Open.2021; 3(8): 1060.     CrossRef
  • Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
    Yin Li, Xue Yang, Peijing Yan, Tong Sun, Zhi Zeng, Sheyu Li
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
    Marina Treskova-Schwarzbach, Laura Haas, Sarah Reda, Antonia Pilic, Anna Borodova, Kasra Karimi, Judith Koch, Teresa Nygren, Stefan Scholz, Viktoria Schönfeld, Sabine Vygen-Bonnet, Ole Wichmann, Thomas Harder
    BMC Medicine.2021;[Epub]     CrossRef
  • COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
    Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
  • High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
    Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 800.     CrossRef
  • Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
    Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
    E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
    Kardiologiia.2021; 61(9): 20.     CrossRef
  • Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
    Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545.     CrossRef
  • COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
    Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Decision Trees: Predictions of Global Vulnerability to Coronavirus Outbreaks
    Moacir José da Silva
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
    Liman Luo, Menglu Fu, Yuanyuan Li, Shuiqing Hu, Jinlan Luo, Zhihui Chen, Jing Yu, Wenhua Li, Ruolan Dong, Yan Yang, Ling Tu, Xizhen Xu
    Clinical Cardiology.2020; 43(12): 1478.     CrossRef
  • The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
    Antonia Anna Lukito, Raymond Pranata, Joshua Henrina, Michael Anthonius Lim, Sherly Lawrensia, Ketut Suastika
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2177.     CrossRef
  • Risk Factors on the Progression to Clinical Outcomes of COVID-19 Patients in South Korea: Using National Data
    Seon-Rye Kim, Seoul-Hee Nam, Yu-Rin Kim
    International Journal of Environmental Research and Public Health.2020; 17(23): 8847.     CrossRef
  • Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea
    Ji Hong You, Sang Ah Lee, Sung-Youn Chun, Sun Ok Song, Byung-Wan Lee, Dae Jung Kim, Edward J. Boyko
    Endocrinology and Metabolism.2020; 35(4): 901.     CrossRef
Complications
Article image
Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence
Jeongmin Lee, Tong Min Kim, Hyunah Kim, Seung-Hwan Lee, Jae Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim
Diabetes Metab J. 2020;44(4):555-565.   Published online May 8, 2020
DOI: https://doi.org/10.4093/dmj.2019.0064
  • 7,560 View
  • 121 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Some patients admitted to hospitals for glycemic control experience hypoglycemia despite regular meals and despite adhering to standard blood glucose control protocols. Different factors can have a negative impact on blood glucose control and prognosis after discharge. This study investigated risk factors for hypoglycemia and its effects on glycemic control during the hospitalization of patients in the general ward.

Methods

This retrospective study included patients who were admitted between 2009 and 2018. Patients were provided regular meals at fixed times according to ideal body weights during hospitalization. We categorized the patients into two groups: those with and those without hypoglycemia during hospitalization.

Results

Of the 3,031 patients, 379 experienced at least one episode of hypoglycemia during hospitalization (HYPO group). Hypoglycemia occurred more frequently particularly in cases of premixed insulin therapy. Compared with the control group, the HYPO group was older (61.0±16.8 years vs. 59.1±16.5 years, P=0.035), with more females (60.4% vs. 49.6%, P<0.001), lower body mass index (BMI) (23.5±4.2 kg/m2 vs. 25.1±4.4 kg/m2, P<0.001), and higher prevalence of type 1 diabetes mellitus (6.1% vs. 2.6%, P<0.001), They had longer hospital stay (11.1±13.5 days vs. 7.6±4.6 days, P<0.001). After discharge the HYPO group had lower glycosylated hemoglobin reduction rate (−2.0%±0.2% vs. −2.5%±0.1%, P=0.003) and tended to have more frequent cases of cardiovascular disease.

Conclusion

Hypoglycemia occurred more frequently in older female patients with lower BMI and was associated with longer hospital stay and poorer glycemic control after discharge. Therefore, clinicians must carefully ensure that patients do not experience hypoglycemia during hospitalization.

Citations

Citations to this article as recorded by  
  • Hypoglycemia in hospitalized patients: A sleeping monster
    Swarna Deepak Kuragayala, Sumita Nayak, Khalid Khatib
    Muller Journal of Medical Sciences and Research.2024; 15(1): 5.     CrossRef
  • Acute kidney injury: a strong risk factor for hypoglycaemia in hospitalized patients with type 2 diabetes
    Ana Carreira, Pedro Castro, Filipe Mira, Miguel Melo, Pedro Ribeiro, Lèlita Santos
    Acta Diabetologica.2023; 60(9): 1179.     CrossRef
  • Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study
    Jae‐Seung Yun, Kyungdo Han, Yong‐Moon Park, Eugene Han, Yong‐ho Lee, Seung‐Hyun Ko
    Journal of Diabetes Investigation.2022; 13(9): 1533.     CrossRef
  • Predicting hypoglycemia in hospitalized patients with diabetes: A derivation and validation study
    Michal Elbaz, Jeries Nashashibi, Shiri Kushnir, Leonard Leibovici
    Diabetes Research and Clinical Practice.2021; 171: 108611.     CrossRef
  • Hospital care: improving outcomes in type 1 diabetes
    Schafer Boeder, Kristen Kulasa
    Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(1): 14.     CrossRef
  • Data Pseudonymization in a Range That Does Not Affect Data Quality: Correlation with the Degree of Participation of Clinicians
    Soo-Yong Shin, Hun-Sung Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Letter: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence (Diabetes Metab J 2020;44:555-65)
    Sung-Woo Kim
    Diabetes & Metabolism Journal.2020; 44(5): 775.     CrossRef
  • Response: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence (Diabetes Metab J 2020;44:555-65)
    Jeongmin Lee, Hun-Sung Kim
    Diabetes & Metabolism Journal.2020; 44(5): 779.     CrossRef
  • Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
    Niki Katsiki, Kalliopi Kotsa, Anca P. Stoian, Dimitri P. Mikhailidis
    Current Pharmaceutical Design.2020; 26(43): 5637.     CrossRef
Brief Report
Cardiovascular risk/Epidemiology
Article image
Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction
Jae-Wook Chung, Yeong-Seon Park, Jeong-Eon Seo, Yeseul Son, Cheol-Woo Oh, Chan-Hee Lee, Jong-Ho Nam, Jung-Hee Lee, Jang-Won Son, Ung Kim, Jong-Seon Park, Kyu-Chang Won, Dong-Gu Shin
Diabetes Metab J. 2021;45(2):270-274.   Published online April 16, 2020
DOI: https://doi.org/10.4093/dmj.2019.0164
  • 6,654 View
  • 128 Download
  • 8 Web of Science
  • 8 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFPubReader   ePub   

This study aimed to determine the impact of dysglycemia on myocardial injury and cardiac dysfunction in acute myocardial infarctions (AMIs). From 2005 to 2016, a total of 1,593 patients with AMIs who underwent percutaneous coronary intervention were enrolled. The patients were classified into five groups according to the admission glucose level: ≤80, 81 to 140, 141 to 200, 201 to 260, and ≥261 mg/dL. The clinical and echocardiographic parameters and 30-day mortality were analyzed. The peak troponin I and white blood cell levels had a positive linear relationship to the admission glucose level. The left ventricular ejection fraction had an inverted U-shape trend, and the E/E' ratio was U-shaped based on euglycemia. The 30-day mortality also increased as the admission glucose increased, and the cut-off value for predicting the mortality was 202.5 mg/dL. Dysglycemia, especially hyperglycemia, appears to be associated with myocardial injury and could be another adjunctive parameter for predicting mortality in patients with AMIs.

Citations

Citations to this article as recorded by  
  • Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea
    Ji Hye Huh, Sang Wook Park, Tae-Hwa Go, Dae Ryong Kang, Sang-Hak Lee, Jang-Young Kim
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Association of admission hyperglycemia and all-cause mortality in acute myocardial infarction with percutaneous coronary intervention: A dose–response meta-analysis
    Shao-Yong Cheng, Hao Wang, Shi-Hua Lin, Jin-Hui Wen, Ling-Ling Ma, Xiao-Ce Dai
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Metabolism.2022; 137: 155327.     CrossRef
  • Basic types of the first-day glycemia in acute myocardial infarction: Prognostic, diagnostic, threshold and target glycemia
    Goran Koracevic, Milan Djordjevic
    Primary Care Diabetes.2021; 15(3): 614.     CrossRef
  • Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction (Diabetes Metab J 2021;45:270-4)
    Bo-Yeon Kim
    Diabetes & Metabolism Journal.2021; 45(5): 787.     CrossRef
  • Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction (Diabetes Metab J 2021;45:270-4)
    Chan-Hee Lee
    Diabetes & Metabolism Journal.2021; 45(5): 791.     CrossRef
  • The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes
    Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2021; 36(5): 977.     CrossRef
  • Effect of Admission Hyperglycemia on Short-Term Prognosis of Patients with Non-ST Elevation Acute Coronary Syndrome without Diabetes Mellitus
    Wei Liu, Zhijuan Li, Shiying Xing, Yanwei Xu, Gaetano Santulli
    Journal of Diabetes Research.2021; 2021: 1.     CrossRef
Original Article
Epidemiology
Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study
Sen Li, Jiaxin Wang, Biao Zhang, Xinyi Li, Yuan Liu
Diabetes Metab J. 2019;43(3):319-341.   Published online April 19, 2019
DOI: https://doi.org/10.4093/dmj.2018.0060
  • 23,359 View
  • 318 Download
  • 145 Web of Science
  • 160 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

To investigate whether diabetes contributes to mortality for major types of diseases.

Methods

Six National Health and Nutrition Examination Survey data cycles (1999 to 2000, 2001 to 2002, 2003 to 2004, 2005 to 2006, 2007 to 2008, and 2009 to 2010) and their linked mortality files were used. A population of 15,513 participants was included according to the availability of diabetes and mortality status.

Results

Participants with diabetes tended to have higher all-cause mortality and mortality due to cardiovascular disease, cancer, chronic lower respiratory diseases, cerebrovascular disease, influenza and pneumonia, and kidney disease. Confounder-adjusted Cox proportional hazard models showed that both diagnosed diabetes category (yes or no) and diabetes status (diabetes, prediabetes, or no diabetes) were associated with all-cause mortality and with mortality due to cardiovascular disease, chronic lower respiratory diseases, influenza and pneumonia, and kidney disease. No associations were found for cancer-, accidents-, or Alzheimer's disease-related mortality.

Conclusion

The current study's findings provide epidemiological evidence that diagnosed diabetes at the baseline is associated with increased mortality risk due to cardiovascular disease, chronic lower respiratory diseases, influenza and pneumonia, and kidney disease, but not with cancer or Alzheimer's disease.

Citations

Citations to this article as recorded by  
  • Contribution of infection to mortality in people with type 2 diabetes: a population-based cohort study using electronic records
    Iain M. Carey, Julia A. Critchley, Umar A.R. Chaudhry, Stephen DeWilde, Elizabeth S. Limb, Liza Bowen, Selma Audi, Derek G. Cook, Peter H. Whincup, Naveed Sattar, Arshia Panahloo, Tess Harris
    The Lancet Regional Health - Europe.2025; 48: 101147.     CrossRef
  • Association of type 2 diabetes mellitus with dementia‐related and non–dementia‐related mortality among postmenopausal women: A secondary competing risks analysis of the women's health initiative
    Tyler J. Titcomb, Phyllis Richey, Ramon Casanova, Lawrence S. Phillips, Simin Liu, Shama D. Karanth, Nazmus Saquib, Tomas Nuño, JoAnn E. Manson, Aladdin H. Shadyab, Longjian Liu, Terry L. Wahls, Linda G. Snetselaar, Robert B. Wallace, Wei Bao
    Alzheimer's & Dementia.2024; 20(1): 234.     CrossRef
  • Antiglycation potential of metal ions and polyphenolic extract of chickpea on thiol-protease inhibitor: A management for diabetic complications
    Mohd Shahnawaz Khan, Sheraz Ahmad Bhat, Monnera Saud Albagmi, Mohammed Arshad, Mohammad Tarique, Bilqees Bano
    Saudi Pharmaceutical Journal.2024; 32(1): 101916.     CrossRef
  • GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
    Mainak Banerjee, Rimesh Pal, Indira Maisnam, Satinath Mukhopadhyay
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(1): 102943.     CrossRef
  • Assessment of the radial peripapillary capillary plexus and retinal nerve fiber layer thickness in diabetic patients in comparison to normal age-matched individuals
    Christina S.I. Farag, Heba M.A. El-Saied, Hala M. El-Mofty, Randa M.A.M. El-Mofty
    Journal of the Egyptian Ophthalmological Society.2024; 117(1): 43.     CrossRef
  • Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus
    Cheol-Won Jang, Tae Yang Yu, Jin Woo Jeong, Se Eun Ha, Rajan Singh, Moon Young Lee, Seungil Ro
    Journal of Personalized Medicine.2024; 14(3): 280.     CrossRef
  • The Benefits and Harms of Lung Cancer Screening in Individuals With Comorbidities
    Minal S. Kale, Keith Sigel, Arushi Arora, Bart S. Ferket, Juan Wisnivesky, Chung Yin Kong
    JTO Clinical and Research Reports.2024; 5(3): 100635.     CrossRef
  • Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki
    PLOS ONE.2024; 19(2): e0299035.     CrossRef
  • Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus
    Shatha M. Alobaid, Rahaf M. Alshahrani, Asma S. Alonazi, Nawal M. Alrasheed, Maha A. Alamin, Tahani K. Alshammari, Anfal F. Bin Dayel, Doaa M. Elnagar, Rana R. Alotaibi, Lama A. Almuthnabi, Dalia H. Almasud, Shahad E. Al-Ammar, Shahad O. Almadhi, Reema A.
    Pharmaceuticals.2024; 17(3): 374.     CrossRef
  • Effects of high-intensity interval training and its different protocols on lipid profile and glycaemic control in type 2 diabetes: A meta-analysis
    Nandiny Paula Cavalli, Mariana Brondani de Mello, Natiele Camponogara Righi, Felipe Barreto Schuch, Luis Ulisses Signori, Antônio Marcos Vargas da Silva
    Journal of Sports Sciences.2024; 42(4): 333.     CrossRef
  • Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus
    Ashwin Kumar Shukla, Komal Awasthi, Kauser Usman, Monisha Banerjee
    World Journal of Diabetes.2024; 15(4): 606.     CrossRef
  • Precision Medicine in Bariatric Procedures
    Khushboo Gala, Wissam Ghusn, Andres Acosta
    Gastrointestinal Endoscopy Clinics of North America.2024; 34(4): 765.     CrossRef
  • Gamma‐glutamyl transferase and the risk of all‐cause and disease‐specific mortality in patients with diabetes: A nationwide cohort study
    Goh Eun Chung, Su‐Min Jeong, Su Jong Yu, Jeong‐Ju Yoo, Yuri Cho, Kyu‐na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho
    Journal of Diabetes.2024;[Epub]     CrossRef
  • Trends in cause-specific mortality among people with type 2 and type 1 diabetes from 2002 to 2019: a Danish population-based study
    Tinne Laurberg, Susanne B. Graversen, Annelli Sandbæk, Sarah H. Wild, Rimke C. Vos, Henrik Støvring
    The Lancet Regional Health - Europe.2024; 41: 100909.     CrossRef
  • Behavioral Therapy for People With Diabetes Who Smoke: A Scoping Review
    Roberta Sammut, Joseph Grech, Riccardo Polosa, Davide Campagna, Agostino Di Ciaula, Tabinda Dugal, Andre Kenge, Anoop Misra, Syed Abbas Raza, Cristina Russo, Noel Somasundaram, Magdalena Walicka, Le Dinh Phoung, Graziella Chiara Prezzavento, Mirko Casu, G
    Journal of Primary Care & Community Health.2024;[Epub]     CrossRef
  • Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
    Sung Won Chung, Hye-Sung Moon, Hyunjae Shin, Hyein Han, Sehoon Park, Heejin Cho, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Sung-Ho Won, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Ki Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Yoon Jun Kim
    Hepatology.2024; 80(3): 633.     CrossRef
  • The Incidence of Type 2 Diabetes Mellitus and Weight Gain in People Living with HIV Receiving a Dolutegravir-Based Antiretroviral Therapy in Addis Ababa, Ethiopia: A Pilot Single-Arm Historical Cohort Study
    Tariku Shimels, Arebu Issa Bilal, Desta Samuel, Desalew Gedamu, Eden Solomon, Zewdneh Shewamene
    Venereology.2024; 3(2): 96.     CrossRef
  • Nerolidol Alleviates Oxidative Stress and Inflammation in Diabetic Retinopathy Mediated by High Glucose through Ameliorating Nrf2/HO-1 Pathway
    Changhong Li, Buchao Shi, Dong Li, Hui Li
    Pharmacognosy Magazine.2024; 20(4): 1313.     CrossRef
  • Low-carbohydrate diet for people with type 2 diabetes mellitus
    Mariana Andrea Burgos, Diego Ivaldi, Gisela Oltra, Camila Micaela Escobar Liquitay, Luis Garegnani
    Cochrane Database of Systematic Reviews.2024;[Epub]     CrossRef
  • Impact of integrative care on cardiovascular disease risk in newly diagnosed type 2 diabetes mellitus patients: A BI-VitalLife Cohort study
    Tanawat Khunlertkit, Teeradache Viangteeravat, Panupong Wangprapa, Suthee Siriwechdaruk, Jeremy Mark Ford, Krit Pongpirul, Amirmohammad Khalaji
    PLOS ONE.2024; 19(5): e0302438.     CrossRef
  • Exploring the diabesity characteristics and associated all-cause mortality at a population level: results from a small European island state
    Sarah Cuschieri, Andrea Cuschieri, Elizabeth Grech, Amber Marie Coleiro, Amy Carabott, Axel Tonna, Dalton Borg, Desiree Sant, Elissa Sultana, Kathleen Ellul, Kristina Marie Scerri, Kylie Psaila, Grazia Magro, Nicole Attard, Ylenia Borg
    Journal of Public Health.2024;[Epub]     CrossRef
  • Comparison between in-person, telehealth, and combination visits among veterans treated in a pharmacist-led diabetes management clinic
    Olivia Yip, Evon Du, Candis M. Morello, Mark Bounthavong
    Journal of the American Pharmacists Association.2024; 64(4): 102121.     CrossRef
  • Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
    Minji Sohn, Seoungyeon Nam, Michael A. Nauck, Soo Lim
    BMC Medicine.2024;[Epub]     CrossRef
  • Differential impacts of fat and muscle mass on cardiovascular and non‐cardiovascular mortality in individuals with type 2 diabetes
    Jie Guo, Yuxia Wei, Emerald G. Heiland, Anna Marseglia
    Journal of Cachexia, Sarcopenia and Muscle.2024; 15(5): 1930.     CrossRef
  • Insulin resistance in nonobese type 2 diabetic Goto Kakizaki rats is associated with a proinflammatory T lymphocyte profile
    Tiago Bertola Lobato, Richelieau Manoel, Ana Carolina Gomes Pereira, Ilana Souza Correa, Patrícia Nancy Iser‐Bem, Elvirah Samantha de Sousa Santos, Joice Naiara Bertaglia Pereira, Maria Janaína Leite de Araújo, João Carlos de Oliveira Borges, Janaina Ribe
    FEBS Letters.2024; 598(20): 2566.     CrossRef
  • Naringin Prevents Diabetic-Induced Dysmetabolism in Male Wistar Rats by Modulating GSK-3 Activities and Oxidative Stress-Dependent Pathways
    Kazeem Bidemi Okesina, Adeyemi Fatai Odetayo, Wale Johnson Adeyemi, Akeem Ayodeji Okesina, Grace Edet Bassey, Luqman Aribidesi Olayaki
    Cell Biochemistry and Biophysics.2024; 82(4): 3559.     CrossRef
  • Association Between Intraoperative Cataract Surgical Complications and Mortality
    Sophia Sidhu, Nathan C. Grove, Jennifer L. Patnaik, Anne M. Lynch, Karen L. Christopher
    Ophthalmic Epidemiology.2024; : 1.     CrossRef
  • Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population
    Eric J. Palecek, Margaret M. Kimzey, Jingwen Zhang, Justin Marsden, Chloe Bays, William P. Moran, Patrick D. Mauldin, Andrew D. Schreiner
    Journal of Investigative Medicine.2024; 72(8): 911.     CrossRef
  • Development and validation of a nomogram of all-cause mortality in adult Americans with diabetes
    Xia Shen, Xiao Hua Zhang, Long Yang, Peng Fei Wang, Jian Feng Zhang, Shao Zheng Song, Lei Jiang
    Scientific Reports.2024;[Epub]     CrossRef
  • Identification of pancreatin inhibitors from Thai medicinal Piper plants for antidiabetic and anti-obesity activities using high-performance thin-layer chromatography-bioautographic assay
    Jiranuch Mingmuang, Phichaporn Bunwatcharaphansakun, Utid Suriya, Weerachai Pipatrattanaseree, Tushar Andriyas, Rossarin Tansawat, Chaisak Chansriniyom, Wanchai De-Eknamkul
    Journal of Chromatography A.2024; 1736: 465358.     CrossRef
  • Insulinemic potential of diet and the risk of type 2 diabetes: a meta-analysis and systematic review
    Hossein Farhadnejad, Mehrnaz Abbasi, Hamid Ahmadirad, Morteza Omrani, Mitra Kazemi Jahromi, Mostafa Norouzzadeh, Niloufar Saber, Farshad Teymoori, Parvin Mirmiran
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • Related factors with NCD in developing countries: economic, diet and risk factors dimensions
    Sergio Arturo Dominguez Miranda, Roman Rodríguez Aguilar
    EAI Endorsed Transactions on Pervasive Health and Technology.2024;[Epub]     CrossRef
  • Effect of GLP-1 Receptor Agonists on Renal Functions and Diabetic Nephropathy in Type 2 Diabetes Mellitus (T2DM) Patients: A Systematic Review and Meta-Analysis
    Ali J Mohamed, Ali H AlSaffar, Ali A Mohamed , Mohamed H Khamis, Ahmed A Khalaf, Husain J AlAradi, Abdulla I Abuhamaid, Ali H Sanad, Hasan L Abbas, Abdulla M Abdulla, Osama A Alkhamis
    Cureus.2024;[Epub]     CrossRef
  • Phytochemical profiling from Dioscorea bulbifera L. bulbils using LC-MS, proximate analysis and antidiabetic activity: in vitro and in silico approaches
    Asmita Rayamajhi, Deepa Karki, Anuraj Phunyal, Asmita Sapkota, Bishnu Adhikari, Achyut Adhikari
    International Journal of Food Properties.2024; 27(1): 1396.     CrossRef
  • What is the optimal range of fasting stress hyperglycemia ratio for all-cause mortality in American adults: An observational study
    Jian Li, Chao Yu, Xiaolu Hu
    Medicine.2024; 103(43): e40288.     CrossRef
  • New Insights on the potential therapeutic effects of glibenclamide and Obeticholic acid against Alloxan-Induced diabetes mellitus in rat model
    Asmaa A. Aboushouk, Hebatallah M. Saad, Aya H. Rohiem, Dina R.S. Gad El-Karim
    International Immunopharmacology.2024; 143: 113469.     CrossRef
  • Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in China: A National Study
    Yunli Tian, Zixin Qiu, Feixue Wang, Shan Deng, Yue Wang, Zi Wang, Peng Yin, Yong Huo, Maigeng Zhou, Gang Liu, Kai Huang
    Diabetes Care.2024; 47(11): 1969.     CrossRef
  • Exploring the current provision of pancreatic transplantations in low- and middle-income countries: Current landscape, challenges, future prospects
    Hareesha Rishab Bharadwaj, Joecelyn Kirani Tan, Syed Hasham Ali, Muhammad Hamza Shah, Aderinto Nicholas, Khabab Abbasher Hussien Mohamed Ahmed, Khansa Irfan, Priyal Dalal, Aashna Mehta, Wireko Andrew Awuah, Arkadeep Dhali
    World Journal of Gastrointestinal Pathophysiology.2024;[Epub]     CrossRef
  • Salivary TNF-α as a marker of periodontal disease in type 2 diabetes mellitus patients: A cross-sectional study
    Sabiha Abdul Aziz Shaikh, Ceena Denny E, Srikant Natarajan, Nandita KP, Sangeeta Umesh Nayak, Nanditha Sujir
    International Journal of Diabetes in Developing Countries.2024;[Epub]     CrossRef
  • Design of the DAVOS Study: Diabetes Smartphone App, a Fully Automatic Transmission of Data From the Blood Glucose Meter and Insulin Pens Using Wireless Technology to Enhance Diabetes Self-Management—A Study Protocol for a Randomized Controlled Trial
    Franziska Grosser, Sandra Herrmann, Maxi Bretschneider, Patrick Timpel, Janko Schildt, Markus Bentrup, Peter E. H. Schwarz
    Journal of Diabetes Science and Technology.2023; 17(3): 742.     CrossRef
  • Low diet quality is associated with adverse levels of metabolic health markers and clustering of risk factors in adults with type 2 diabetes
    Namrata Sanjeevi, Jeanne H. Freeland‐Graves
    Journal of Human Nutrition and Dietetics.2023; 36(1): 31.     CrossRef
  • Need for improving immunization status and preventive care in diabetes mellitus patients
    Teresa Gisinger, Alexandra Kautzky-Willer, Michael Leutner
    Wiener klinische Wochenschrift.2023; 135(13-14): 336.     CrossRef
  • Nanoparticles encapsulating sesame seeds (Sesamum indicum) oil: Physicochemical, antioxidant and enzymatic inhibition properties
    Narimane Lammari, Mehdi Louaer, Ouahida Louaer, Chawki Bensouici, Ahmed Zermane, Abdelhamid Elaissari, Abdeslam Hassen Meniai
    Journal of Drug Delivery Science and Technology.2023; 79: 104003.     CrossRef
  • Significant Association between Subclinical Left Cardiac Dysfunction and Liver Stiffness in Metabolic Syndrome Patients with Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
    Alexandru Apostu, Daniel Malita, Sergiu-Florin Arnautu, Mirela-Cleopatra Tomescu, Dan Gaiță, Alina Popescu, Ruxandra Mare, Ramona Gidea, Diana-Aurora Arnautu
    Medicina.2023; 59(2): 328.     CrossRef
  • An examination of causal associations and shared risk factors for diabetes and cardiovascular diseases in the East Asian population: A Mendelian randomization study
    Yulin Guo, Jie Gao, Yan Liu, Yanxiong Jia, Xiangguang An, Xitao Zhang, Pixiong Su
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Synthesis, Cytotoxicity and In Vitro α-Glucosidase Inhibition of New N-Substituted Glitazone and Rhodanine Derivatives
    N. R. Tshiluka, M. V. Bvumbi, S. S. Mnyakeni-Moleele
    Russian Journal of Bioorganic Chemistry.2023; 49(2): 384.     CrossRef
  • Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes
    Khaled Aburisheh, Mohammad F. AlKheraiji, Saleh I. Alwalan, Arthur C. Isnani, Mohamed Rafiullah, Muhammad Mujammami, Assim A. Alfadda
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • Adapted Diabetes Complications Severity Index and Charlson Comorbidity Index in predicting all-cause and cause-specific mortality among patients with type 2 diabetes
    Yu-Wen Hu, Chiu-Mei Yeh, Chia-Jen Liu, Tzeng-Ji Chen, Nicole Huang, Yiing-Jenq Chou
    BMJ Open Diabetes Research & Care.2023; 11(2): e003262.     CrossRef
  • Influenza: Diabetes as a risk factor for severe related-outcomes and the effectiveness of vaccination in diabetic population. A meta-analysis of observational studies
    Ilaria Dicembrini, Giovanni Antonio Silverii, Alessandra Clerico, Riccardo Fornengo, Giovanni Gabutti, Valeria Sordi, Silvio Tafuri, Ottavia Peruzzi, Edoardo Mannucci
    Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(6): 1099.     CrossRef
  • Research progress on classification, sources and functions of dietary polyphenols for prevention and treatment of chronic diseases
    Wei Li, Haihong Chen, Bing Xu, Yi Wang, Canyang Zhang, Yong Cao, Xinhui Xing
    Journal of Future Foods.2023; 3(4): 289.     CrossRef
  • Greater efficiency of polyherbal drug encapsulated biosynthesized chitosan nano-biopolymer on diabetes and its complications
    G. Revathi, S. Elavarasi, K. Saravanan, M. Ashokkumar, Chukwuebuka Egbuna
    International Journal of Biological Macromolecules.2023; 240: 124445.     CrossRef
  • Variations in all-cause mortality, premature mortality and cause-specific mortality among persons with diabetes in Ontario, Canada
    Laura C Rosella, Kathy Kornas, Ednah Negatu, Limei Zhou
    BMJ Open Diabetes Research & Care.2023; 11(3): e003378.     CrossRef
  • The relationship between family support and the level of self care in type 2 diabetes patients
    Fatma Gul Zeren, Ozlem Canbolat
    Primary Care Diabetes.2023; 17(4): 341.     CrossRef
  • Diabetes mellitus-related hospital admissions and prescriptions of antidiabetic agents in England and Wales: an ecological study
    Gayda Abdel Rahman AbuHammad, Abdallah Y. Naser, Loay Khaled Mohammad Hassouneh
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • Administration of alloxan and streptozotocin in Sprague Dawley rats and the challenges in producing diabetes model
    Indah Fajarwati, Dedy Duryadi Solihin, Tutik Wresdiyati, Irmanida Batubara
    IOP Conference Series: Earth and Environmental Science.2023; 1174(1): 012035.     CrossRef
  • Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation
    A H M Nurun Nabi, Akio Ebihara, Hossain Uddin Shekhar
    World Journal of Virology.2023; 12(3): 151.     CrossRef
  • Risk Stratification for Herpes Simplex Virus Pneumonia Using Elastic Net Penalized Cox Proportional Hazard Algorithm with Enhanced Explainability
    Yu-Chiang Wang, Wan-Ying Lin, Yi-Ju Tseng, Yiwen Fu, Weijia Li, Yu-Chen Huang, Hsin-Yao Wang
    Journal of Clinical Medicine.2023; 12(13): 4489.     CrossRef
  • Bee Honey Extract Attenuates Hyperglycemia in Induced Type 1 Diabetes: Impact of Antioxidant and Angiogenesis Activities on Diabetic Severity In Vivo
    Ahmed H. Alghamdi, Ibrahim M. Shatla, Soliman Shreed, Atif H. Khirelsied, Mohamed F. El-Refaei
    Applied Sciences.2023; 13(14): 8045.     CrossRef
  • Increased Left Atrial Stiffness is Significantly Associated with Paroxysmal Atrial Fibrillation in Diabetic Patients
    Diana-Aurora Arnautu, Sergiu-Florin Arnautu, Mirela-Cleopatra Tomescu, Silvia Luca, Constantin-Tudor Luca
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2077.     CrossRef
  • Cost-effectiveness analysis of implementing polygenic risk score in a workplace cardiovascular disease prevention program
    Deo Mujwara, Jen Kintzle, Paolo Di Domenico, George B. Busby, Giordano Bottà
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Diabetes associates with mortality in critically ill patients with SARS-CoV-2 pneumonia: No diabetes paradox in COVID-19
    Priscila Bellaver, Larissa Schneider, Ariell F. Schaeffer, Lilian Rodrigues Henrique, Joíza Lins Camargo, Fernando Gerchman, Cristiane B. Leitão, Tatiana H. Rech
    Heliyon.2023; 9(8): e18554.     CrossRef
  • New Insights into the Role of Oxidative Stress in the Development of Diabetes Mellitus and Its Complications
    Julia Matzenbacher dos Santos, Qing Zhong, Sandra A. Benite-Ribeiro, Thiago Gomes Heck
    Journal of Diabetes Research.2023; 2023: 1.     CrossRef
  • A paradigm shift for cardiovascular outcome evaluation in diabetes: Major adverse cardiovascular events (MACE) to major adverse vascular events (MAVE)
    Ashu Rastogi, Anand Sudhayakumar, Nicolaas C. Schaper, Edward B. Jude
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(11): 102875.     CrossRef
  • Assessing Elevated Blood Glucose Levels Through Blood Glucose Evaluation and Monitoring Using Machine Learning and Wearable Photoplethysmography Sensors: Algorithm Development and Validation
    Bohan Shi, Satvinder Singh Dhaliwal, Marcus Soo, Cheri Chan, Jocelin Wong, Natalie W C Lam, Entong Zhou, Vivien Paitimusa, Kum Yin Loke, Joel Chin, Mei Tuan Chua, Kathy Chiew Suan Liaw, Amos W H Lim, Fadil Fatin Insyirah, Shih-Cheng Yen, Arthur Tay, Seng
    JMIR AI.2023; 2: e48340.     CrossRef
  • Cost-Utility of an Exercise Referral Scheme Versus Doing Nothing in Flemish Adults: Exploring the Impact of Key Assumptions
    Amber Werbrouck, Masja Schmidt, Koen Putman, Steven Simoens, Nick Verhaeghe, Lieven Annemans
    Journal of Physical Activity and Health.2023; : 1.     CrossRef
  • Community-based models of care for management of type 2 diabetes mellitus among non-pregnant adults in sub-Saharan Africa: A scoping review
    Emmanuel Firima, Lucia Gonzalez, Fabiola Ursprung, Elena Robinson, Jacqueline Huber, Jennifer M. Belus, Fabian Raeber, Ravi Gupta, Gibrilla F. Deen, Alain Amstutz, Bailah Leigh, Maja Weisser, Niklaus Daniel Labhardt, Rehana Abdus Salam
    PLOS ONE.2023; 18(11): e0278353.     CrossRef
  • Effect of Empowerment Model-Based Program on Quality of Life in Patients with Type 2 Diabetes
    Hossein Ebrahimi, Mahdi Sadeghi, Seyed-Mahdi Esmaeili, Farahnaz Janmohammadi, Elahess Bahonar
    Iranian Journal of Nursing and Midwifery Research.2023; 28(1): 99.     CrossRef
  • Omega-3 supplementation and diabetes: A systematic review and meta-analysis
    Felipe Mendes Delpino, Lílian Munhoz Figueiredo, Bruna Gonçalves Cordeiro da Silva, Taiciane Gonçalves da Silva, Gicele Costa Mintem, Renata Moraes Bielemann, Denise Petrucci Gigante
    Critical Reviews in Food Science and Nutrition.2022; 62(16): 4435.     CrossRef
  • The effect of real‐time monitoring of physical activity intensity in diabetic patients
    Rumi Tanaka, Kimie Fujita, Satoko Maeno, Kanako Yakushiji, Satomi Tanaka, Keizo Ohnaka, Kenji Ashida, Shohei Sakamoto, Masatoshi Nomura
    Japan Journal of Nursing Science.2022;[Epub]     CrossRef
  • Factors associated with influenza vaccine coverage among patients with diabetes: Korea National Health and Nutrition Examination Survey 2016–2018
    A. Lum Han
    International Journal of Diabetes in Developing Countries.2022; 42(2): 297.     CrossRef
  • Interacción entre el estadio de la enfermedad renal crónica y la diabetes mellitus como factores asociados con mortalidad en pacientes con enfermedad renal crónica: un estudio de cohortes externas
    Laura E. Villegas Sierra, Melisa Buriticá Agudelo, Carlos Enrique Yepes Delgado, Yanett Marcela Montoya Jaramillo, Fabián Jaimes Barragan
    Nefrología.2022; 42(5): 540.     CrossRef
  • Influence of glucose supplementation on biofilm formation of Candida albicans and Candida glabrata isolated from diabetic and non-diabetic individuals
    Pedro Castania Amadio Domingues, Viviane de Cássia Oliveira, Felipe Lazarini Bim, Carolina Patrícia Aires, André Pereira dos Santos, Denise Tornavoi de Castro, Cláudia Helena Silva-Lovato, Denise de Andrade, Evandro Watanabe
    Archives of Oral Biology.2022; 134: 105339.     CrossRef
  • The influence of the disclosure of diabetes on the cognitive, physical ability and diabetes self‐management in diabetic employed adults in Saudi Arabia
    Sitah Alshutwi, Eman Miligi, Lujain Alhumidan, Adel F. Almutairi
    Nursing Open.2022; 9(2): 978.     CrossRef
  • Effect of fermented cassava tuber on the gene expression of PI3K/Akt signaling and AMPK pathway in STZ-NA-induced diabetic rats
    Rio Jati Kusuma, Desty Ervira Puspaningtyas, Puspita Mardika Sari
    Nutrition & Food Science .2022; 52(2): 213.     CrossRef
  • A fractional order control model for Diabetes and COVID-19 co-dynamics with Mittag-Leffler function
    Andrew Omame, Ugochukwu K. Nwajeri, M. Abbas, Chibueze P. Onyenegecha
    Alexandria Engineering Journal.2022; 61(10): 7619.     CrossRef
  • Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care
    Ileana Mardare, Stephen M. Campbell, Johanna C. Meyer, Israel Abebrese Sefah, Amos Massele, Brian Godman
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Dyslipidemia Among Patients With Type 1 Diabetes and Its Associated Factors in Saudi Arabia: An Analytical Cross-Sectional Study
    Abdullah A Alrasheed
    Cureus.2022;[Epub]     CrossRef
  • Prickly Pear Cacti (Opuntia spp.) Cladodes as a Functional Ingredient for Hyperglycemia Management: A Brief Narrative Review
    Rao Raahim Kashif, Nathan M. D’Cunha, Duane D. Mellor, Natalie I. Alexopoulos, Domenico Sergi, Nenad Naumovski
    Medicina.2022; 58(2): 300.     CrossRef
  • Machine learning for predicting chronic diseases: a systematic review
    F.M. Delpino, Â.K. Costa, S.R. Farias, A.D.P. Chiavegatto Filho, R.A. Arcêncio, B.P. Nunes
    Public Health.2022; 205: 14.     CrossRef
  • Effects of blueberry and cranberry on type 2 diabetes parameters in individuals with or without diabetes: A systematic review and meta-analysis of randomized clinical trials
    Felipe Mendes Delpino, Lílian Munhoz Figueiredo, Taiciane Gonçalves da Silva, Thaynã Ramos Flores
    Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(5): 1093.     CrossRef
  • Momordica charantia nanoparticles potentiate insulin release and modulate antioxidant gene expression in pancreas of diabetic rats
    Olusola Olalekan Elekofehinti
    Egyptian Journal of Medical Human Genetics.2022;[Epub]     CrossRef
  • GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
    Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo
    Kidney Research and Clinical Practice.2022; 41(2): 136.     CrossRef
  • Pharmacological Study: Synergistic Antidiabetic Activity of Cinnamon Bark and Zingiber Extract in Streptozotocin-Induced Diabetic Rats
    Eva Nurinda, Nurul Kusumawardani, Ari Susiana Wulandari , Annisa Fatmawati, E. Emelda, Husnatun Nisa, Nurjani A. Hasan, Wahyu Fajar Iriyanti, Mardiatun Rohmah, Puji Lestari, Veriani Aprilia
    Open Access Macedonian Journal of Medical Sciences.2022; 10(T8): 1.     CrossRef
  • Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk‐Enhancing Factor in the Pooled Cohort Equation: A Cost‐Effectiveness Analysis Study
    Deo Mujwara, Geoffrey Henno, Stephen T. Vernon, Siyang Peng, Paolo Di Domenico, Brock Schroeder, George B. Busby, Gemma A Figtree, Giordano Bottà
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • Comparison of mechanistic pathways of bariatric surgery in patients with diabetes mellitus: A Bayesian network meta‐analysis
    Chaoxing Lin, Trevor James Jun‐Ming Yeong, Wen Hui Lim, Cheng Han Ng, Chun En Yau, Yip Han Chin, Mark D. Muthiah, Poay Huan Loh, Roger S. Y. Foo, Shao Feng Mok, Asim Shabbir, Georgios K. Dimitriadis, Chin Meng Khoo, Nicholas W. S. Chew
    Obesity.2022; 30(7): 1380.     CrossRef
  • Diabetes and COVID-19: Biological profile of type 2 diabetic patients with COVID-19 in Pointe-Noire, Congo
    Anicet Boumba Luc Magloire, Batchy Aladin Atandi, Elenga-Bongo Charley, Pouki Freddy Saturnin, Kibouilou Fredy, Balanda Christ Nkouanga, Dabo Tidiane Cheick Ahmed, Wahar Saar Abdoul, Mahouanga Didel Mampassi, Voumbi Ghislain Loubano, Moukassa Donatien
    Global Journal of Clinical Virology.2022; 7(1): 001.     CrossRef
  • Integrated Nutritional Supports for Diabetic Patients During COVID-19 Infection: A Comprehensive Review
    A.K. Obidul Huq, Abu Naim Mohammad Bazlur Rahim, S.M. Golam Moktadir, Ielias Uddin, Mohammad Zahidul Manir, Muhammad Abu Bakr Siddique, Khaleda Islam, Md. Sirajul Islam
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Mechanisms of COVID-19 pathogenesis in diabetes
    Chandrakala Aluganti Narasimhulu, Dinender K. Singla
    American Journal of Physiology-Heart and Circulatory Physiology.2022; 323(3): H403.     CrossRef
  • Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee
    Endocrinology and Metabolism.2022; 37(3): 466.     CrossRef
  • Gender difference in association between diabetes mellitus and all-cause mortality in atrial fibrillation patients
    Li Tian, Yan-min Yang, Jun Zhu, Han Zhang, Xing-hui Shao
    Journal of Diabetes and its Complications.2022; 36(9): 108265.     CrossRef
  • An Overview of Diabetes Mellitus in Egypt and the Significance of Integrating Preventive Cardiology in Diabetes Management
    Mohamed R Abouzid, Karim Ali, Ibrahim Elkhawas, Shorouk M Elshafei
    Cureus.2022;[Epub]     CrossRef
  • The association between diabetes mellitus and functionality in knee osteoarthritis: a cross-sectional study
    Serdar KAYMAZ, Sanem Aslıhan AYKAN
    Journal of Health Sciences and Medicine.2022; 5(4): 1114.     CrossRef
  • In-hospital hyperglycemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysis of observational studies prior to COVID-19
    Rahul D Barmanray, Nathan Cheuk, Spiros Fourlanos, Peter B Greenberg, Peter G Colman, Leon J Worth
    BMJ Open Diabetes Research & Care.2022; 10(4): e002880.     CrossRef
  • The association between leukocyte telomere length and chronic obstructive pulmonary disease is partially mediated by inflammation: a meta-analysis and population-based mediation study
    Tieshan Wang, Zhaoqi Jia, Sen Li, Yuxin Li, Tingting Yu, Tao Lu, Yuanyuan Shi
    BMC Pulmonary Medicine.2022;[Epub]     CrossRef
  • The Influence of Diabetic Peripheral Neuropathy on the Duration of Sciatic Nerve Block with 1.3% Liposomal Bupivacaine and 0.25% Bupivacaine Hydrochloride in a Mouse Model
    Liljana Markova, Erika Cvetko, Chiedozie Kenneth Ugwoke, Simon Horvat, Nejc Umek, Tatjana Stopar Pintarič
    Pharmaceutics.2022; 14(9): 1824.     CrossRef
  • Free, Conjugated, and Bound Phenolics in Peel and Pulp from Four Wampee Varieties: Relationship between Phenolic Composition and Bio-Activities by Multivariate Analysis
    Xue Lin, Yousheng Shi, Pan Wen, Xiaoping Hu, Lu Wang
    Antioxidants.2022; 11(9): 1831.     CrossRef
  • Protocol: Developing a framework to improve glycaemic control among patients with type 2 diabetes mellitus in Kinshasa, Democratic Republic of the Congo
    Jean-Pierre Fina Lubaki, Olufemi Babatunde Omole, Joel Msafiri Francis, David Desseauve
    PLOS ONE.2022; 17(9): e0268177.     CrossRef
  • Triglyceride-glucose index is associated with poor sleep quality in apparently healthy subjects: A cross-sectional study
    Daniela Carolina Avelino, Alessandra da Silva, Larissa Oliveira Chaves, Júlia Cristina Cardoso Carraro, Fernanda de Carvalho Vidigal, Josefina Bressan
    Archives of Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • Molecular mechanisms interlinking biological clock and diabetes mellitus: Effective tools for better management
    Chandrasekaran Sankaranarayanan, Perumal Subramanian
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(11): 102639.     CrossRef
  • Amyloid Fibrillation of Insulin: Amelioration Strategies and Implications for Translation
    Megren H. A. Fagihi, Sourav Bhattacharjee
    ACS Pharmacology & Translational Science.2022; 5(11): 1050.     CrossRef
  • Potential Roles of Anti-Inflammatory Plant-Derived Bioactive Compounds Targeting Inflammation in Microvascular Complications of Diabetes
    Yahia A. Kaabi
    Molecules.2022; 27(21): 7352.     CrossRef
  • Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk
    Seohyun Kim, Gyuri Kim, Jae Hyeon Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Re-understanding and focusing on normoalbuminuric diabetic kidney disease
    Na An, Bi-tao Wu, Yu-wei Yang, Zheng-hong Huang, Jia-fu Feng
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Coexistent Lichen Amyloidosis and Acquired Reactive Perforating Collagenosis in Type 2 Diabetes Mellitus and Post-Thyroidectomy Hypothyroidism Due to Papillary Thyroid Carcinoma: A Rare Case
    Eva Krishna Sutedja, Muhamad Radyn Haryadi Widjaya, Hartati Purbo Dharmadji, Pati Aji Achdiat, Laila Tsaqilah
    International Medical Case Reports Journal.2022; Volume 15: 745.     CrossRef
  • Interaction between the stage of chronic kidney disease and diabetes mellitus as factors associated with mortality in chronic kidney disease patients: An external cohort study
    Laura E. Villegas Sierra, Melisa Buriticá Agudelo, Carlos Enrique Yepes Delgado, Yanett Marcela Montoya Jaramillo, Fabián Jaimes Barragan
    Nefrología (English Edition).2022; 42(5): 540.     CrossRef
  • Effects of Pea Protein on Satiety, Postprandial Glucose Response and Appetite Hormones: A Literature Review
    Amy Choi
    Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal.2022; 6(10): 1.     CrossRef
  • Hemoglobin glycation index is associated with incident chronic kidney disease in subjects with impaired glucose metabolism: A 10-year longitudinal cohort study
    Wonjin Kim, Taehwa Go, Dae Ryong Kang, Eun Jig Lee, Ji Hye Huh
    Journal of Diabetes and its Complications.2021; 35(1): 107760.     CrossRef
  • Coronavirus Disease 2019 (SARS-CoV-2) and polycystic ovarian disease: Is there a higher risk for these women?
    Giuseppe Morgante, Libera Troìa, Vincenzo De Leo
    The Journal of Steroid Biochemistry and Molecular Biology.2021; 205: 105770.     CrossRef
  • Regional differences in diabetes across Europe – regression and causal forest analyses
    Péter Elek, Anikó Bíró
    Economics & Human Biology.2021; 40: 100948.     CrossRef
  • Active ingredients and mechanisms of Phellinus linteus (grown on Rosa multiflora) for alleviation of Type 2 diabetes mellitus through network pharmacology
    Ki Kwang Oh, Md. Adnan, Dong Ha Cho
    Gene.2021; 768: 145320.     CrossRef
  • Application of Telemedicine in Diabetes Care: The Time is Now
    Felix Aberer, Daniel A. Hochfellner, Julia K. Mader
    Diabetes Therapy.2021; 12(3): 629.     CrossRef
  • Long-term outcomes after kidney transplant failure and variables related to risk of death and probability of retransplant: Results from a single-center cohort study in Brazil
    Lúcio R. Requião-Moura, Cássio R. Moreira Albino, Paula Rebello Bicalho, Érika de Arruda Ferraz, Luciana Mello de Mello Barros Pires, Maurício Fregonesi Rodrigues da Silva, Alvaro Pacheco-Silva, Justyna Gołębiewska
    PLOS ONE.2021; 16(1): e0245628.     CrossRef
  • Estimating the disease burden of Korean type 2 diabetes mellitus patients considering its complications
    Juyoung Kim, Seok-Jun Yoon, Min-Woo Jo, Brecht Devleesschauwer
    PLOS ONE.2021; 16(2): e0246635.     CrossRef
  • Susceptibility for Some Infectious Diseases in Patients With Diabetes: The Key Role of Glycemia
    Jesús Chávez-Reyes, Carlos E. Escárcega-González, Erika Chavira-Suárez, Angel León-Buitimea, Priscila Vázquez-León, José R. Morones-Ramírez, Carlos M. Villalón, Andrés Quintanar-Stephano, Bruno A. Marichal-Cancino
    Frontiers in Public Health.2021;[Epub]     CrossRef
  • Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study
    Zobida Islam, Shamima Akter, Yosuke Inoue, Huan Hu, Keisuke Kuwahara, Tohru Nakagawa, Toru Honda, Shuichiro Yamamoto, Hiroko Okazaki, Toshiaki Miyamoto, Takayuki Ogasawara, Naoko Sasaki, Akihiko Uehara, Makoto Yamamoto, Takeshi Kochi, Masafumi Eguchi, Tai
    Diabetes Care.2021; 44(3): 757.     CrossRef
  • Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis
    Hamid Mirjalili, Seyed Alireza Dastgheib, Seyed Hossein Shaker, Reza Bahrami, Mahta Mazaheri, Seyed Mohamad Hossein Sadr-Bafghi, Jalal Sadeghizadeh-Yazdi, Hossein Neamatzadeh
    Journal of Diabetes & Metabolic Disorders.2021; 20(1): 905.     CrossRef
  • Prevalence and associated factors of diabetes mellitus among tuberculosis patients in Brunei Darussalam: A 6-year retrospective cohort study
    Nurfakhrina Omar, Justin Wong, Kyaw Thu, Md Fathi Alikhan, Liling Chaw
    International Journal of Infectious Diseases.2021; 105: 267.     CrossRef
  • Diabetes and COVID-19
    Zohair Jamil Gazzaz
    Open Life Sciences.2021; 16(1): 297.     CrossRef
  • Review of potential risk groups for coronavirus disease 2019 (COVID-19)
    M. Naveed, M. Naeem, M. ur Rahman, M. Gul Hilal, M.A. Kakakhel, G. Ali, A. Hassan
    New Microbes and New Infections.2021; 41: 100849.     CrossRef
  • COVID-19 from the interdisciplinary standpoint. Round table
    M. N. Mamedov, Yu. V. Rodionova, I. S. Yavelov, M. I. Smirnova, E. N. Dudinskaya, V. I. Potievskaya
    Cardiovascular Therapy and Prevention.2021; 20(3): 2849.     CrossRef
  • Diabetes is a major cause of influenza-associated mortality in Mexico
    A. Gómez-Gómez, E.L. Sánchez-Ramos, D.E. Noyola
    Revue d'Épidémiologie et de Santé Publique.2021; 69(4): 205.     CrossRef
  • RETRACTED ARTICLE: Ameliorative potential of Operculina turpethum against streptozotocin-induced diabetes in rats: biochemical and histopathological studies
    Neeraj Choudhary, Gopal L. Khatik, Rekha Sharma, Navneet Khurana, Richard Lobo, Shvetank Bhatt, Devesh Tewari, Ashish Suttee
    3 Biotech.2021;[Epub]     CrossRef
  • Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
    Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Ma
    Current Medical Research and Opinion.2021; 37(9): 1529.     CrossRef
  • Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review
    Yasaman Sharifi, Moloud Payab, Erfan Mohammadi-Vajari, Seyed Morsal Mosallami Aghili, Farshad Sharifi, Neda Mehrdad, Elham Kashani, Zhaleh Shadman, Bagher Larijani, Mahbube Ebrahimpur
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1743.     CrossRef
  • Association of ACE I/D and PAI-1 4G/5G polymorphisms with susceptibility to type 2 diabetes mellitus
    Somaye Miri, Mohammad Hasan Sheikhha, Seyed Alireza Dastgheib, Seyed Amir Shaker, Hossein Neamatzadeh
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1191.     CrossRef
  • Assessment and Management of Diabetic Patients During the COVID-19 Pandemic
    Amit K Verma, Mirza Masroor Ali Beg, Deepti Bhatt, Kapil Dev, Mohammed A Alsahli, Arshad Husain Rahmani, Yamini Goyal
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 3131.     CrossRef
  • Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K
    Ahmed Iqbal, Marni Greig, Muhammad Fahad Arshad, Thomas H. Julian, Sher Ee Tan, Jackie Elliott
    Diabetes Research and Clinical Practice.2021; 178: 108955.     CrossRef
  • Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study
    Emilio Ortega, Rosa Corcoy, Mònica Gratacòs, Francesc Xavier Cos Claramunt, Manel Mata-Cases, Ramon Puig-Treserra, Jordi Real, Bogdan Vlacho, Esmeralda Castelblanco, Pere Domingo, Kamlesh Khunti, Josep Franch-Nadal, Didac Mauricio
    BMJ Open.2021; 11(7): e051237.     CrossRef
  • Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients
    Juan Alonso Leon-Abarca, Arianna Portmann-Baracco, Mayte Bryce-Alberti, Carlos Ruiz-Sánchez, Roberto Alfonso Accinelli, Jorge Soliz, Gustavo Francisco Gonzales, Chiara Lazzeri
    PLOS ONE.2021; 16(8): e0255144.     CrossRef
  • Botanical Interventions to Improve Glucose Control and Options for Diabetes Therapy
    Peter Smoak, Susan J. Burke, J. Jason Collier
    SN Comprehensive Clinical Medicine.2021; 3(12): 2465.     CrossRef
  • Antidiabetic bioactive compounds from Tetrastigma angustifolia (Roxb.) Deb and Oxalis debilis Kunth.: Validation of ethnomedicinal claim by in vitro and in silico studies
    Julfikar Ali Junejo, Kamaruz Zaman, Mithun Rudrapal, Ismail Celik, Emmanuel Ifeanyi Attah
    South African Journal of Botany.2021; 143: 164.     CrossRef
  • SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
    Moein Ala
    Endocrinology.2021;[Epub]     CrossRef
  • Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial
    Jean-Eric Tarride, Mansoor Husain, Andreas Andersen, Jens Gundgaard, Maria Luckevich, Thomas Mark, Lily Wagner, Thomas R. Pieber
    Journal of Medical Economics.2021; 24(1): 1318.     CrossRef
  • Traditional Uses, Pharmacological Effects, and Molecular Mechanisms of Licorice in Potential Therapy of COVID-19
    Qian-hui Zhang, Hao-zhou Huang, Min Qiu, Zhen-feng Wu, Zhan-chang Xin, Xin-fu Cai, Qiang Shang, Jun-zhi Lin, Ding-kun Zhang, Li Han
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus
    Lata Rani, Ajmer Singh Grewal, Neelam Sharma, Sukhbir Singh
    Mini-Reviews in Medicinal Chemistry.2021; 21(4): 426.     CrossRef
  • Low Levels of Influenza Vaccine Uptake among the Diabetic Population in Spain: A Time Trend Study from 2011 to 2020
    Jose J. Zamorano-Leon, Rodrigo Jimenez-Garcia, Ana Lopez-de-Andres, Javier de-Miguel-Diez, David Carabantes-Alarcon, Romana Albaladejo-Vicente, Rosa Villanueva-Orbaiz, Khaoula Zekri-Nechar, Sara Sanz-Rojo
    Journal of Clinical Medicine.2021; 11(1): 68.     CrossRef
  • Effects of Short-term Mobile Application Use on Weight Reduction for Patients with Type 2 Diabetes
    Seung Eun Lee, Su-Kyung Park, Ye-Seul Park, Kyoung-Ah Kim, Han Seok Choi, Sang Woo Oh
    Journal of Obesity & Metabolic Syndrome.2021; 30(4): 345.     CrossRef
  • Diabetes mellitus in combination with COVID-19: modern views on therapy
    V.I. Tsymbaliuk, M.D. Tronko, Y.G. Antypkin, S.V. Kushnirenko, V.V. Popova
    REPRODUCTIVE ENDOCRINOLOGY.2021; (57): 8.     CrossRef
  • Dietary aldose reductase inhibitors and prevention of diabetic complications
    Ameena Anjum, Janamolla Sreeja, Yarlagadda Swapna, Rajesh Bolleddu, Sama Venkatesh
    Indian Journal of Health Sciences and Biomedical Research (KLEU).2021; 14(2): 194.     CrossRef
  • Cohort Profile: The Maule Cohort (MAUCO)
    Catterina Ferreccio, Andrea Huidobro, Sandra Cortés, Claudia Bambs, Pablo Toro, Vanessa Van De Wyngard, Johanna Acevedo, Fabio Paredes, Pía Venegas, Hugo Verdejo, Ximena Oyarzún-González, Paz Cook, Pablo F Castro, Claudia Foerster, Claudio Vargas, Jill Ko
    International Journal of Epidemiology.2020; 49(3): 760.     CrossRef
  • Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus
    MengHee Tan, Mark Paul MacEachern
    Clinics in Geriatric Medicine.2020; 36(3): 457.     CrossRef
  • Increased Mortality Risk in People with Type 2 Diabetes Mellitus in Lithuania
    Donata Linkeviciute-Ulinskiene, Auguste Kaceniene, Audrius Dulskas, Ausvydas Patasius, Lina Zabuliene, Giedre Smailyte
    International Journal of Environmental Research and Public Health.2020; 17(18): 6870.     CrossRef
  • Proteinuria Is Associated with Carotid Artery Atherosclerosis in Non-Albuminuric Type 2 Diabetes: A Cross-Sectional Study
    Jaehyun Bae, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Journal of Clinical Medicine.2020; 9(1): 136.     CrossRef
  • COVID-19 and diabetes: Knowledge in progress
    Akhtar Hussain, Bishwajit Bhowmik, Nayla Cristina do Vale Moreira
    Diabetes Research and Clinical Practice.2020; 162: 108142.     CrossRef
  • Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study
    Bo Kyung Koo, Woo-Young Chung, Min Kyong Moon
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Risk Factors in and Long-Term Survival of Patients with Post-Transplantation Diabetes Mellitus: A Retrospective Cohort Study
    Ching-Yao Cheng, Cheng-Hsu Chen, Ming-Fen Wu, Ming-Ju Wu, Jun-Peng Chen, Ying-Mei Liu, Yu-Chi Hou, Hue-Yu Wang
    International Journal of Environmental Research and Public Health.2020; 17(12): 4581.     CrossRef
  • Fasting Plasma Glucose Variability and Gastric Cancer Risk in Individuals Without Diabetes Mellitus: A Nationwide Population-Based Cohort Study
    So-hyeon Hong, Eunjin Noh, Jinsil Kim, Soon Young Hwang, Jun A. Kim, You-Bin Lee, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
    Clinical and Translational Gastroenterology.2020; 11(9): e00221.     CrossRef
  • Trimetazidine Inhibits Renal Tubular Epithelial Cells to Mesenchymal Transition in Diabetic Rats via Upregulation of Sirt1
    Yong Yang, Yong Wang, Zuowen He, Yunchang Liu, Chen Chen, Yan Wang, Dao Wen Wang, Hong Wang
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
    Stephane Demine, Michael L. Schulte, Paul R. Territo, Decio L. Eizirik
    International Journal of Molecular Sciences.2020; 21(19): 7274.     CrossRef
  • The role of dental insurance in mitigating mortality among working‐age U.S. adults with periodontitis
    Naveed Sadiq, Janice C. Probst, Anwar T. Merchant, Amy B. Martin, Deepika Shrestha, M. Mahmud Khan
    Journal of Clinical Periodontology.2020; 47(11): 1294.     CrossRef
  • Antidiabetic Activity of Triterpenoids from Anisophyllea disticha
    Miftahul Fikriyah, Muhammad Almurdani, Yum Eryanti, Hilwan Y. Teruna
    Journal of Physics: Conference Series.2020; 1655(1): 012033.     CrossRef
  • Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study
    Dina H. Kassem, Mohamed M. Kamal
    Stem Cell Research & Therapy.2020;[Epub]     CrossRef
  • Loss of Smell in COVID-19 Patients: Lessons and Opportunities
    Dennis Mathew
    Frontiers in Human Neuroscience.2020;[Epub]     CrossRef
  • Diabetes mellitus and COVID-19: current issues of pathogenesis, clinic and therapy. Literature review
    В. І. Цимбалюк, М. Д. Тронько, Ю. Г. Антипкін, В. В. Попова
    REPRODUCTIVE ENDOCRINOLOGY.2020; (54): 8.     CrossRef
  • Increased Age of Death and Change in Causes of Death Among Persons With Diabetes Mellitus From the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • Purva Rupeeyam of bhela indriya sthana-an explorative study
    Kshama Gupta, Prasad Mamidi
    International Journal of Complementary & Alternative Medicine.2020; 13(6): 228.     CrossRef
  • The COVID-19 pandemic and diabetes mellitus
    Athanasia Papazafiropoulou, Stavros Antonopoulos
    Archives of Medical Science – Atherosclerotic Diseases.2020; 5(1): 200.     CrossRef
  • Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
    Sunghwan Suh, Kwang-Won Kim
    Diabetes & Metabolism Journal.2019; 43(6): 733.     CrossRef
  • Diabetes Mellitus, Still Major Threat to Mortality from Various Causes
    Nam Hoon Kim
    Diabetes & Metabolism Journal.2019; 43(3): 273.     CrossRef
  • The Need to Improve the Quality of Diabetes Care in Korea
    Seung Jin Han, Dae Jung Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP